@@@@@

#USAIC20 Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK GWAS not easy to find which gene drives the association Functional Genomics gene by gene with phenotypes using machine learning significant help

Srihari Gopal

@sgopal2

Enjoyed hearing enthusiasm for Neuroscience R&D by Roy Vagelos at #USAIC20. Wonderful interview by Mathai Mammen

@JanssenGlobal

Show this thread

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Nina Kjellson, General Partner, Canaan Data science is a winner in Healthcare Women – Data Science is an excellent match

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Merck & Co. Data on Patients and identification who will benefit fro which therapy cultural bias risk aversion

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Najat Khan, Chief Operating Officer, Janssen R&D Data Sciences, Johnson & Johnson Data Validation Deployment of algorithms embed data by type early on in the crisis to understand the disease

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Sastry Chilukuri, President, Acorn AI- Medidata Opportunities in Data Science in Paharma COVID-19 and Data Science

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Maya Said, Chief Executive Officer, Outcomes4Me Cancer patients taking change of their care Digital Health – consumerization of Health, patient demand to be part of the decision, part the information FDA launched a Program Project Patient Voice

USAIC

@USAIC

We’re taking a quick break at #USAIC20 before our next panel on rare diseases starts at 12:20pm EDT. USAIC would like to thank our Sponsors and Partners for supporting this year’s digital event.

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Roy Vagelos, Chairman of the Board, Regeneron HIV-AIDS: reverse transcriptase converted a lethal disease to a chronic disease, tried hard to make vaccine – the science was not there

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals Congratulates Big Pharma for taking the challenge on COVID-19 Vaccine, Antibody and anti-viral Government funding Merck was independent from Government – to be able to set the price

Dr Kapil Khambholja

@kapilmk

Christopher Viehbacher, Gurnet Point Capital touches very sensitive topic at #USAIC20 He claims that we are never going to have real innovation out of big pharma! Well this isn’t new but not entirely true either… any more thoughts?

Show this thread

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Daphne Zohar, Founder & CEO, PureTech Health Disease focus, best science is the decision factors

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Christopher Viehbacher, Managing Partner, Gurnet Point Capital Dream of every Biotech – get Big Pharma coming to acquire and pay a lot Morph and adapt

anju ghangurde

@scripanjug

Biogen’s chair Papadopoulos big co mergers is an attempt to solve problems; typically driven by patent expirations.. #usaic20

@USAIC

anju ghangurde

@scripanjug

Chris Viehbacher/Gurnet Point Capital on US election: industry will work with whoever wins; we’ll have to ‘morph & adapt’ #usaic20

@USAIC

Dr Kapil Khambholja

@kapilmk

@daphnezohar

@PureTechH

talks about various philosophies and key reasons why certain projects/molecules are killed early. My counter questions- What are chances of losing hope little early? Do small #biopharma publish negative results to aid to the knowledge pool? #USAIC20

Show this thread

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Rehan Verjee, President, EMD Serono Antibody cytoxic avoidance with precision

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute DNA repair and epignetics are the future of medicine

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute COlonorectal cancer is increasing immuno therapy 5 drugs marketed 30% cancer patients are treated early detection key vs metastatic 10% of cancer are inherited treatment early

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Rehan Verjee, President, EMD Serono Charities funding cancer research – were impacted and resources will come later and in decreased amount New opportunities support access to Medicine improve investment across the board

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Philip Larsen, Global Head of Research, Bayer AG Repurposing drugs as antiviral from drug screening innovating methods Cytokine storm in OCVID-19 – kinase inhibitors may be antiviral data of tested positive allows research of pathway in new ways

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber 3,000 Telemedicine session in the first week of the Pandemic vs 300 before – patient come back visits patient happy with Telemedicine team virtually need be reimbursed same rate working remotely

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School New normal as a result of the pandemic role of personalized medicine

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Rehan Verjee, President, EMD Serono entire volume of clinical trials at Roche went down same at EMD delay of 6 month, some were to be initiated but was put on hold Charities funding cancer research were impacted and resources will come later smaller

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute Dana Farber saw impact of COVID-19 on immunosuppressed patients coming in for Cancer Tx – switch from IV Tx to Oral 96% decrease in screenings due to Pandemic – increase with Cancer

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Pharma’s obligation for next generations requires investment in R&D vs Politicians running for 4 years Patients must come first vs shareholders vs R&D investment in 2011

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Antibiotic research at Merck – no market incentives on pricing for Merck to invest in antibiotics people will die from bacterial resistance next pandemic be bacterial

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Strategies of Merck = “Medicine is for the People not for Profit” – Ketruda in India is not reembureable in India and million are in need it Partnership are encouraged

Dr Kapil Khambholja

@kapilmk

@biogen

Chairman Stelios Papadopoulos asks #KennethFrazier if wealthy nations will try to secure large proportion of #COVID19 drugs/vaccines. #KennethFrazie rightly mentions: pharma industry’s responsibility to balance the access to diff countries during pandemic. #USAIC20

Show this thread

USAIC

@USAIC

Merck CEO Ken Frazier interviewed by Biogen Chairman Stelios Papadopoulos: #COVID19 vaccine product profile should be 1 dose that can be deployed globally and administered easily #USAIC20 $MRK $BIIB usaindiachamber.org/agenda.php

Dr Kapil Khambholja

@kapilmk

Almost 60% participants at #USAIC20 feel that MNCs are more likely to run their #clinicalTrials in #INDIA seeing changing environment here, reveals the poll. Exciting time ahead for scientific fraternity as this can substantially increase the speed of #DrugDevelopment globally

Show this thread

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health Vaccine in clinical trials, public need to return for 2nd shot, hesitancy Who will get the Vaccine first in the US most vulnerable of those causing transmission Pharma’s risk

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health Testing – PCR expensive does not enable quick testing is expensive result come transmission occurred Antibody testing CRISPR test based Vaccine in clinical trials

Aviva Lev-Ari

@AVIVA1950

#USAIC20 Dr Andrew Plump, President of R&D, Takeda Pharmaceuticals COllaboration effort around the Globe in the Pandemic therapy solutions including Vaccines

https://pharmaceuticalintelligence.com/2020/09/04/tweet-collection-by-pharma_bi-and-aviva1950-and-re-tweets-for-e-proceedings-14th-annual-biopharma-healthcare-summit-friday-september-4-2020-8-am-est-to-3-30-pm-est-virtual-editio/

14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Posted in BioTechnology - Venture Creation, Conference Coverage with Social Media, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment on July 28, 2020| Leave a Comment »

14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

Founder & Director, LPBI Group

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

http://www.usaindiachamber.org

2021 summit- June 22. Marriott Cambridge, Massachusetts, USA

LPBI’s 2020 VISION

@pharma_BI

@AVIVA1950

#USAIC20

USAIC has created an ecosystem committed to driving a global dialogue on BioPharma & Healthcare innovation, attracting a diverse mix of senior industry professionals and catalyzing partnerships, new ideas, networks and regulatory reform. This unique platform creates mutually beneficial opportunities and relationships for the global Life Sciences & Healthcare industry.

14^th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Speakers
Kenneth Frazier Chairman of the Board & CEO Merck & Co.	Dr. Andrew Plump President of R&D Takeda Pharmaceuticals	Dr. Laurie Glimcher President & CEO Dana-Farber Cancer Institute	Dr. Roy Vagelos Chairman of the Board Regeneron	Dr. Stelios Papadopoulos Chairman of the Board Biogen

Dr. Mathai Mammen Global Head of Janssen R&D Johnson & Johnson	Christopher Viehbacher Managing Partner Gurnet Point Capital	Hari Bhartia Founder & Co-Chairman Jubilant Bhartia Group	Dr. Hal Barron President, R&D and CSO GlaxoSmithKline	Prof. K. Vijay Raghavan Principal Scientific Advisor Government of India

Sanat Chattopadhyay President- Merck Manufacturing Division Merck & Co.	Dr. George Yancopoulos Co-Founder, President & CSO Regeneron	Kiran Mazumdar Shaw Executive Chairperson Biocon	Dr. Elias Zerhouni Professor Emeritus Johns Hopkins University	Dr. David Reese Executive Vice President- R&D Amgen

Dr. Alfred Sandrock Executive Vice President, R&D Biogen	Dr. Naresh Trehan Chairman Medanta – the Medicity	Dr. Najat Khan Chief Operating Officer, Data Sciences Janssen- Johnson & Johnson	Dr. Richard Hatchett Chief Executive Officer CEPI	Amitabh Kant Chief Executive Officer NITI Aayog

Dr. Martin Mackay Co-Founder Rallybio	Dr. Daniel Curran Head of the Rare Diseases TA Takeda Pharmaceuticals	Daphne Zohar Founder & CEO PureTech Health	Dr. David Meeker Chairman & CEO Rhythm Pharmaceuticals	Dr. John Orloff EVP and Head of R&D Alexion

Dr. Mandeep Bhandari Joint Secretary Ministry of Health, India	Dr. Barry Bloom Professor & former Dean Harvard School of Public Health	Dr. Anne Heatherington Head of Data Sciences Institute Takeda Pharmaceuticals	Dr. Philip Larsen Global Head of Research Bayer AG	Dr. Timothy Yu Assistant Professor in Pediatrics Harvard Medical School

Rehan Verjee President EMD Serono	Sastry Chilukuri Executive Vice President Medidata	Arpa Garay President, Commercial Analytics Merck & Co.	Dr. William Chin Professor of Medicine, Emeritus Harvard Medical School	Dr. V G Somani Drugs Controller General of India Government of India

Dr. Rajeev Venkayya President-Global Vaccines Takeda	Dr. Steve Uden Co-Founder Rallybio	Muna Bhanji SVP, Global Market Access Merck & Co.	Dr. Maya Said Chief Executive Officer Outcomes4Me	Dr. Raju Kucherlapati Professor of Genetics Harvard Medical School

Dr. Tony Ho Head of R&D CRISPR Therapeutics	Dr. Sanjeev Sinha Professor of Medicine All India Institute of Medical Sciences	Nina Kjellson General Partner Canaan	Dr. Michael Rosenblatt Chief Medical Officer Flagship Pioneering	Dr. Shiv Kumar Sarin Director Institute of Liver & Biliary Sciences

Matt Wilsey Co-Founder & Chairman Grace Science Foundation	Dr. Samuel Waksal Founder Meira GTx	Dr. Alise Reicin Former President, Global Clinical Dev. Celgene	Dr. Toni Choueiri Director Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute	Dr. Dhaval Patel EVP & Chief Scientific Officer UCB

Dr. Nirmal Kumar Ganguly Former Director General Indian Council of Medical Research	Dr. Peter Mueller President The Muller Health Foundation	Dr. Timothy Clackson President & CTO Xilio Therapeutics

14^th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020,

8 AM EST to 3-30 PM EST – Virtual Edition

Chair and Master of Ceremonies (Emcee)– Dr. Andrew Plump, President of R&D, Takeda Pharmaceuticals

Timings are Eastern Standard Time (EST)

Time	Topic
8 AM – 8-10 AM	Welcome address: Karun Rishi, President, USAIC COVID-19 Pandemic is a Global crisis India can play a special role in R&D and in Manufacturing including Vaccine development Opening comments: Dr Andrew Plump, President of R&D, Takeda Pharmaceuticals Global Summit around the World – JP Morgan of the East as we were called – it is Now a Global Conference vs East Coast Record number of Drugs approved as New Drugs with special quality explosion of modality of therapies to include Gene Therapy Billion underserved vs N-of-One drug India’s President Modi allow healthcare access to 1/2Billion collaboration across the World COVID Alliance in vaccine development Global effort, China recovery is remarkable India battle the infection and it is growing – Public Health Remarkable Speakers
8-10 AM – 8-50 AM	Panel Discussion- COVID-19: Where are we now? Where are we going? Panelists: Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health Testing – PCR expensive does not enable quick testing is expensive result come transmission occurred Antibody testing CRISPR test based Vaccine in clinical trials, public need to return for 2nd shot, hesitancy Who will get the Vaccine first? in the US most vulnerable of those causing transmission Pharma takes risk when efficacious level is unknown Dr. George Yancopoulos, Co-Founder, President & CSO, Regeneron Repurpose – be careful Ebola vaccine development approach is been REUSED for COVID-19 Existential threat by Disease – preparedness is ridiculous as size of investment – far where we need to be Untreatable disease burden COVID-19 cost of healthcare calls massive increases as a society and Private sector Moderna invested in new technology from Academe to the Industry Universal HealthCare will cripple the the healthcare systems Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Safety in proof of concept Children focus for emergency use validation of repurpose drugs oral vaccine involve sequential processing, approval and TRUST, concerns about risks accelerate the process is the opportunity Dr. Rajeev Venkayya, President of the Global Vaccine Business Unit, Takeda Public confidence in COVID-19 Vaccine The Group with concerns at present is larger than 15 years ago due to the accelerate process od the development process political influences on CDC emergency authorization given prior to election hesitancy – influence of social media, conspiracies Transparency by Pharma and by Regulatory Agencies Independent reviews Dr. Richard Hatchett, CEO, Coalition for Epidemic Preparedness Innovations (CEPI) 78 countries ready to participate, Healthcare workers priority to be ready end of next year Moderator: Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School
8-50 AM – 8-55 AM	Break + Polling
8-55 AM – 9-10 AM	India Regulatory update Dr. Mandeep Bhandari, Joint Secretary, Ministry of Health & Family Welfare, India COVID related – support for Clinical Trials support to the Industry, innovators, processes and infrastructure is in place Dr. V G Somani, Drug Controller General of India, Central Drug Control Organization partnership, time line, transparency interaction online with regulators 30 days approval pre and post approval – progress achieved Online presubmission very useful to both sides Ecosystems on early development: Gene therapy Moderator: Muna Bhanji, Senior Vice President, Merck & Co. India’s preparedness
9-10 AM – 9-15 AM	Break + Polling
9-15 AM – 9-55 AM	Fireside Chat Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Strategies of Merck = “Medicine is for the People not for Profit” AntiViral – nucleocide – orally bioavailable Vaccine in early development – BSV Vaccine used in EBOLA – attenuated virus vector platform experience – 1 single doze, deployed Globally Vaccine modified Measles Vaccine, novel platform – out patient and Hospital Antibiotic research at Merck – no market incentives on pricing for Merck to invest in antibiotics people will die from bacterial resistance infection and next pandemic will be bacterial not viral Moderator: Dr. Stelios Papadopoulos, Chairman of the Board, Biogen Most important comments on urgency in investment in drug development by multiple constituencies made by Dr. George Yancopoulos, Co-Founder, President & CSO, Regeneron Access to therapy
9-55 AM – 10 AM	Break + Polling
10 AM – 10-40 AM	India Innovation Landscape Panelists: Amitabh Kant, Chief Executive Officer, National Institution for Transforming India (NITI) Innovation in drug discovery collaboration for clinical trial infrastructure BioEconomy BioSimilar the largest number approved anywhere Incentives for size and scale Ingredients manufacturing to become India’s priority Investment in R&D and Human Capital in the BioEconomy Hari Bhartia, Founder & Co-Chairman, Jubilant Bhartia Group US history of innovations cluster and infrastructure: Academe, VC, small medium Biopharma, Government involvement India: Contract research – 20 years history, lagging the ability to take risk Changing, pricing of drug increased, innovating drug for local consumption, and it can be taken to US for a better price Cancer immunology in India under development India was Leading Chemistry Research – China’s government invested and took the market Indian companies bigger in size – free on requirement imposed on China India will be a great supplier to US Market to build high capacity raw materials Dr. K. Vijay Raghavan, Principal Scientific Advisor, Government of India Resources are necessary 30% from Industry vs Government and Academe with great students and labs Indian context – Personalized Medicine – Telemedicine and IT infrastructure allowing innovation in a 1Billion Population- sheer volume of quality professional Dr. Naresh Trehan, Chairman, Medanta – the Medicity Ecosystem ready for Government to promote innovations to conduct clinical trial with global acceptance standard diverse gene pool in population to innovate for new molecule to market Vaccine under development on Phase 1,2,3 – regulatory mechanism is in place genetic drugs, BioSimilar dominance in the market – biotech can do clinical trials in India vs abroad Moderator: Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co. Largest producer of generic drugs antiretroviral drug produced by Indian Pharma Biotech innovations growing middle class – how innovation , infrastructure and shift to research Diversify and become self reliance
10-40 AM – 10-45 AM	Break + Polling
10-45 AM – 11-25 AM	Panel Discussion- Oncology: Changing landscape- COVID learnings and the promise of new technologies Panelists: Dr. Alise Reicin, Former President, Global Clinical Development, Celgene Clinical trial were impacted by association of patients to trials anti bacterial resistance requires investment – needs will be greater for antibiotics in the future Cancer mutation next therapy biomarkers for mutations to be developed Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute Dana Farber saw impact of COVID-19 on immunosuppressant population of patients coming in for Cancer Tx – switch from IV Tx to Oral 96% decrease in screenings due to Pandemic – increase with Cancer diagnosis in coming years No clinical Trials in Cancer were suspended – all continued Telemedicine and working at home very efficient Genomics of COVID-19 studies at Dana Farber same pathway identifies safety and efficacy must be achieved – not to approve drugs without phase I & Phase II endpoints Dr. Philip Larsen, Global Head of Research, Bayer AG Repurposing drugs as antiviral from drug screening innovating methods Cytokine storm in OCVID-19 – kinase inhibitors may be antiviral – dat of tested positive allows research of pathway in new ways Regulatory agencies in US and Europe for types of drugs vs single patient drugs Rehan Verjee, President, EMD Serono entire volume of clinical trials at Roche went down same at EMD delay of 6 month, some were to be initiated but was put on hold Charities funding cancer research – were impacted and resources will come later and in decreased amount New opportunities support access to Medicine improve investment across the board Antibody cytotoxic with precision Dr. Tony Ho, Head of Research and Development, CRISPR Therapeutics challenges overcome by testing at home Moderator: Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School New normal as a result of the pandemic role of personalized medicine Cancer cure – what are the prospects
11-25 AM – 11-30 AM	Break + Polling
11-30 AM – 12-10 PM	Panel Discussion- Industry & Investment Outlook Panelists: Christopher Viehbacher, Managing Partner, Gurnet Point Capital IPOs can have advantages in Pandemics – Travel curtails all deals done virtually in greater efficiency Drug pricing is a target by White house Dream of every Biotech – get Big Pharma coming to acquire and pay a lot Morph and adapt Daphne Zohar, Founder & CEO, PureTech Health kill project early financial incentive not in line in the industry incentive to move resources among project and kill early project experiments to find which project to kill Innovations – pattern recognition, fast followers academic translation Disease focus, best science is the decision factors Dr. Elias Zerhouni, Professor Emeritus, Johns Hopkins University Digital Health CVS opens clinics R&D – Capital is low Network of global innovation hubs vc investor channel like in the past Value of company driven by hits blockbusters Dr. Stelios Papadopoulos, Chairman, Biogen Worst pandemic in our lifetime stock market if hot – in balance in supply and demand, interest rates low, excess supply of equities in entertainment, Travel, hospitality Healthcare was defensive therapeutics needed – opportunity to innovate in HC – shift money from entertainment, Travel hospitality to HC Recovery will shift money away from Healthcare IP Protection and patent expiration – biotech are cases not trends Moderator: Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals Days of Genzyme please tell us about Christopher Viehbacher, Managing Partner, Gurnet Point Capital Moderator Presenter: Dr. Michael Rosenblatt, CEO
12-10 PM – 12-20 PM	Break + Polling
12-20 PM – 1 PM	Panel Discussion- Rare Diseases: No longer forgotten; but more to be achieved ROI is not there, regulatory requirements reduced, Registry Panelists: Dr. Alfred Sandrock, Executive Vice President, Research & Development, Biogen Multiple Sclerosis therapy cost effectiveness is not there vs save a life Appeal opportunity is there and regulators are people Dr. Daniel Curran, Head of the Rare Diseases Therapeutic Area Unit, Takeda Takeda collaborates with Grace Science Foundation Dr. David Meeker, Chairman & CEO , Rhythm Pharmaceuticals Cystic Fibrosis Dr. John Orloff, Head of Research & Development, Alexion ALS Duchenne Muscular Destrophy HUS ASO gene therapy – one time therapy: Valuation for the industry of long term therapy: US (long term non existence) vs Europe and Japan (much appreciated Matt Wilsey, Co-Founder & Chairman, Grace Science Foundation Ultra-rare (500 Patients) vs Ultra Ultra-rare (50 Patients) 70 patients in the World, Grace disease, Parent drive the search for drug Manufacturing cost comes down Price is dynamic Moderator: Dr. Steve Uden, Co-Founder, Rallybio Regulators are people
1 PM – 1-05 PM	Break + Polling
1-05 PM – 1-50 PM	Fireside Chat Dr. Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals Congratulate Big Pharma for taking the challenge on COVID-19 Vaccine, Antibody and anti-viral Government funding Merck was independent from Government – to be independent and be able to set the price HIV-AIDS: reverse transcriptase converted a lethal disease to a chronic disease, tried hard to make vaccine – the science was not there Industry role: Competition of drug discovery capacity is been built, global needs, price need be low for global reach Government is a already a player hoping without a control on pricing 300Million people were treated FREE by Merck’s Family Program HepC 9% in China immunize the newborn with HepB 1994 100% babies immunized – no profit to Merck – eradication of HepB in China Neuro degeneration – science supports drug development Role of R&D Scientists in Drug discovery? Moderator: Dr. Mathai Mammen, Global Head of Janssen Research & Development, Johnson & Johnson COVID-19 drug development: Response by Big Pharma Industry role in Access to medicines, biologics, antibodies, vaccines Role of R&D Scientists in Drug discovery? PAHTN – use Machine Learning on top of data collected routinely,
1-50 PM – 1-55 PM	Break + Polling
1-55 PM – 2-35 PM	Panel Discussion- Digital & Data Science in Healthcare: Pragmatic Insights from the Real-World Panelists: Dr. Anne Heatherington, Head of Data Sciences Institute, Takeda Pharmaceuticals Reliance on Data – AI and Data in Pharma alliance with MIT collaboration of Data for COVID-19 Women need education in STEM and in Data Science Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Merck & Co. Data on Patients and identification who will benefit fro which therapy cultural bias risk aversion Invest early on in STEM Dr. Maya Said, Chief Executive Officer, Outcomes4Me Cancer patients taking change of their care Digital Health – consumerization of Health, patient demand to be part of the decision, part of the information FDA launched a Program Project Patient Voice Project Patient Voice is an online platform for patients and caregivers along with their healthcare providers to look at patient-reported symptom data collected from cancer clinical trials. https://www.fda.gov/about-fda/oncology-center-excellence/project-patient-voice Women should not undersell themselves Dr. Najat Khan, Chief Operating Officer, Janssen R&D Data Sciences, Johnson & Johnson Validation Deployment of algorithms embed data by type early on in the crisis to understand the disease Compare the Big IT-Data and Pharma where are the barriers? STEM and Women in Pharma – the opportunity must be right Nina Kjellson, General Partner, Canaan Data science is a winner in Healthcare Women – Data Science is an excellent match Moderator: Sastry Chilukuri, President, Acorn AI- Medidata Opportunities in Data Science in Pharma COVID-19 and Data Science STEM and Women in Pharma
2-35 PM – 2-40 PM	Break + Polling
2-40 PM – 3-20 PM	Panel Discussion- R&D Strategies and Trends: Innovation – The Big I Panelists: Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals Enter for Plasma and for manufacturing vs discovery Change how pharma behaved inefficiently in the past – with COVID-19 new behaviors in the industry End of Century most diseases could be cured Dr. David Reese, Executive Vice President, Research and Development, Amgen Interaction with regulator was most favorable Dr. Hal Barron, Chief Scientific Officer and President R&D, GlaxoSmithKline Cytokine storm – few approaches Control molecule GSK owned GWAS not easy to find which gene drives the association Functional Genomics gene by gene with phenotypes using machine learning significant help Dr. Mathai Mammen, Global Head of Janssen Research & Development, Johnson & Johnson Neuro-modulation: Symptomology Outcomes – no correlation Vaccine platform used in the past for several vaccines: Selection process from several candidates, cell line enter Clinical waiting for data Using same platform with several proteins – great communality in the development Regulator deepen trust relationship which will carry for the future Pulmonologists and cardiologist in the COVIS-19 Patients – remove drugs monitoring on drugs Moderator: Duval Patel presented the Moderator Moderator: Martin Mackay, Co-Founder, RallyBio
3-20 PM – 3-30 PM	Closing Remarks Every year it is getting better India – innovate and make drugs for every country and for India Diversity and inclusion Leadership in Pharma Industry in all Panels Massive impact can be made

Poll Questions for September 4

Polling Time (EST)	Polling Topic
8-50 AM	COVID-19 PanelQuestion 1: What do you foresee as the most likely outcome of the race to develop a vaccine? Heightened international tensions due to inequities in distribution Use of the vaccine as an instrument of geopolitics Collaboration between governments to use vaccine to end the pandemic All of the above Question 2: What minimum criteria would you like to see for approval of COVID19 vaccines, assuming adequate efficacy? Immune response in people over 60 years Durability of response Antibody plus T-cell response Emergency Use Authorization with caveats followed by final approval
9-10 AM	India Regulatory UpdateHow will MNCs respond to the recent regulatory changes for BioPharmas in India? They are _____ to run clinical trials there: More likely Less likely Equally likely
9-55 AM	Fireside Chat: Ken Frazier The BioPharma industry this year has publicly committed itself to greater diversity. What specific measures do you expect to see? Increasing diversity in clinical trials Increasing diversity at the C-suite and board level Increasing diversity throughout the company All of the above None of the above
10-40 AM	India Innovation LandscapeWhat is the most important step India could take to become a global leader in life sciences innovation?” Implement government policies to incentivize innovative drug development Increase availability of financing for BioPharmas Improve clinical trial infrastructure Increase IP protection
11-25 AM	Oncology PanelQuestion 1: Changes in policy and reimbursement over the next five years will impact innovation in cancer therapeutics Not at all Slightly Moderately Significantly Question 2: What therapeutic innovation do you think will have the biggest impact on cancer in the next five years? Cell-based immunotherapies Antibody-based immunotherapies Bispecific / multi-specific antibodies Antibody drug conjugates
12-10 PM	Industry & Investment Outlook PanelMore and more funding has been going into preclinical companies — do you expect this trend to continue? Yes No R&D Strategies and Trends Panel COVID-19 has led to an unprecedented level of collaboration among stakeholders in the biopharma industry. Where do you expect to see the biggest increase in collaborations post-pandemic? Discovery/preclinical research Clinical development Manufacturing Commercialization
1 PM	Rare Diseases PanelWhat is the biggest barrier to access to Orphan drugs in low-income countries? Price, Access and Availability Disease recognition and diagnosis Lack of patient education regarding new therapies Ultra-rarity of certain diseases creates barriers for BioPharma companies to pursue therapeutic
1-50 PM	Fireside Chat: Roy VagelosQuestion 1: Will pharma’s reputation continue its positive trend or return to negative base line beyond the pandemic Yes No Question 2: COVID-19 has put the spotlight on BioPharma as an essential player in the return to normalcy. What primary action do you think the industry needs to take to maintain a positive reputation beyond the pandemic? Continue developing innovative drug pricing models Increase drug pricing transparency Increase data sharing and transparency Improving availability and access in low income countries
2-35 PM	Digital & Data Sciences PanelWhere has COVID-19 had the biggest impact on your adoption and use of digital health technologies? Remote clinical trials and patient monitoring Real-world data collection and analysis Virtual drug launches

@@@@

In these unprecedented times due to COVID-19, USAIC is offering Free Registration for its annual summit.

Click for free registration

AGENDA & SPEAKERS

Chair and Master of Ceremonies (Emcee)– Dr. Andrew Plump, President of R&D, Takeda Pharmaceuticals
Summit Theme: “From N of One to N of a Billion”

Moderated Fireside Chat- Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. and Stelios Papadopoulos, Chairman of the Board, Biogen
Moderated Fireside Chat- Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals and Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical Companies of Johnson & Johnson
Moderated Fireside Chat- K. VijayRaghavan, Principal Scientific Advisor, Government of India and Amitabh Kant, CEO, National Institution for Transforming India (NITI)

Panel Discussions:

Covid-19: Where are we now? Where are we going?
Oncology: A never ending tunnel?
Rare Diseases: Breaking Barriers for a Healthy Brain
Digital & Data Sciences: Leveraging data and digital to achieve healthcare solutions
Industry & Investment Outlook
R&D Strategies and Trends: Innovation – The Big I

Program and speakers subject to change^*

14^th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Speakers
Kenneth Frazier Chairman of the Board & CEO Merck & Co.	Dr. Andrew Plump President of R&D Takeda Pharmaceuticals	Dr. Laurie Glimcher President & CEO Dana-Farber Cancer Institute	Dr. Roy Vagelos Chairman of the Board Regeneron	Dr. Stelios Papadopoulos Chairman of the Board Biogen

Christopher Viehbacher Managing Partner Gurnet Point Capital	Dr. Mathai Mammen Global Head of R&D Janssen- Johnson & Johnson	Kiran Mazumdar Shaw Chairperson & Managing Director Biocon	Dr. Hal Barron President, R&D and CSO GlaxoSmithKline	Prof. K. Vijay Raghavan Principal Scientific Advisor Government of India

Dr. George Yancopoulos Co-Founder, President & CSO Regeneron	Dr. Elias Zerhouni Professor Emeritus Johns Hopkins University	Daphne Zohar Founder & CEO PureTech Health	Sanat Chattopadhyay President- Merck Manufacturing Division Merck & Co.	Dr. David Reese Executive Vice President- R&D Amgen

Hari Bhartia Founder & Co-Chairman Jubilant Bhartia Group	Dr. Alfred Sandrock Exe Vice President R&D & CMO Biogen	Dr. Najat Khan Chief Operating Officer, Data Sciences Janssen- Johnson & Johnson	Dr. Richard Hatchett Chief Executive Officer CEPI	Amitabh Kant Chief Executive Officer NITI Aayog

Dr. Martin Mackay Co-Founder Rallybio	Dr. Daniel Curran Head of the Rare Diseases TA Takeda Pharmaceuticals	Dr. Alise Reicin Former President, Global Clinical Dev. Celgene	Dr. David Meeker Chairman & CEO Rhythm Pharmaceuticals	Dr. John Orloff EVP and Head of R&D Alexion

Dr. Barry Bloom Professor & former Dean Harvard School of Public Health	Dr. Mandeep Bhandari Joint Secretary Ministry of Health, India	Arpa Garay President, Commercial Analytics Merck & Co.	Dr. Steve Uden Co-Founder Rallybio	Dr. Philip Larsen Global Head of Research Bayer AG

Sastry Chilukuri Executive Vice President Medidata	Dr. William Chin Professor of Medicine, Emeritus Harvard Medical School	Dr. Anne Heatherington Head of Data Sciences Institute Takeda Pharmaceuticals	Dr. V G Somani Drugs Controller General of India Government of India	Dr. Rajeev Venkayya President-Global Vaccines Takeda

Dr. Raju Kucherlapati Professor of Genetics Harvard Medical School	Matt Wilsey Co-Founder & Chairman Grace Science Foundation	Muna Bhanji SVP, Global Market Access Merck & Co.	Dr. Maya Said Chief Executive Officer Outcomes4Me	Rehan Verjee President EMD Serono

SOURCE:

https://usaindiachamber.org/speaker.php

Posted in AI-assisted Cardiac MRI, Artificial intelligence applications for cardiology, Artificial Intelligence Applications in Health Care, Artificial Intelligence in CANCER, Artificial Intelligence in Health Care - Tools & Innovations, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, Artificial Intelligence in Psychiatry, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Coronavirus Gene Expression, COVID-19, Deep Learning in Pathology, Innovations, Population Health Management, Genetics & Pharmaceutical, R&D Expenditure, SARS-CoV-2, Serology tests for coronavirus antibodies, Virus Infective Acute Respiratory Syndrome: SARS-CoV on May 12, 2020| Leave a Comment »

Life Science and Digital Health Investments – 2020 World Medical Innovation Forum – COVID-19, AI – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

2020 World Medical Innovation Forum – COVID-19, AI – Life Science and Digital Health Investments, MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

Life science and digital health investments have continued at a strong pace during the COVID-19 crisis. Senior investment leaders discuss what to expect. Will:

social distancing affect deal making?
key asset categories remain strong – venture, private equity, public offerings, acquisitions?
valuations hold up in some categories while others fall?

Moderator: Roger Kitterman, VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham

Jan Garfinkle, Founder & Manager Partner, Arboretum Ventures, Chair NVCA

Phillip Gross, Managing Director, Adage Capital Management

Christopher Viehbacher, Managing Partner, Gurnet Point Capital

VIEW VIDEOS from the event

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Date: Tuesday, May 12, 2020 at 6:48 AM

To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Subject: REGISTRANT RECAP | World Medical Innovation Forum

Dear World Forum Attendee,

On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators. As promised, we wanted to also share visual Forum session summaries. You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning

We hope you will join us for the 2021 Forum!

Thanks again, Chris

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/04/22/world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-monday-may-11-815-a-m-515-p-m-et/

Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/05/11/tweets-retweets-2020-world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-mond/

https://feinternational.com/blog/how-do-you-value-an-online-business/

Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Symposium: New Drugs on the Horizon Part 3 12:30-1:25 PM

Reporter: Stephen J. Williams, PhD

New Drugs on the Horizon: Part 3
Introduction

Andrew J. Phillips, C4 Therapeutics

symposium brought by AACR CICR and had about 30 proposals for talks and chose three talks
unfortunately the networking event is not possible but hope to see you soon in good health

ABBV-184: A novel survivin specific T cell receptor/CD3 bispecific therapeutic that targets both solid tumor and hematological malignancies

Edward B Reilly
AbbVie Inc. @abbvie

T-cell receptors (TCR) can recognize the intracellular targets whereas antibodies only recognize the 25% of potential extracellular targets
survivin is expressed in multiple cancers and correlates with poor survival and prognosis
CD3 bispecific TCR to survivn (Ab to CD3 on T- cells and TCR to survivin on cancer cells presented in MHC Class A3)
ABBV184 effective in vivo in lung cancer models as single agent;
in humanized mouse tumor models CD3/survivin bispecific can recruit T cells into solid tumors; multiple immune cells CD4 and CD8 positive T cells were found to infiltrate into tumor
therapeutic window as measured by cytokine release assays in tumor vs. normal cells very wide (>25 fold)
ABBV184 does not bind platelets and has good in vivo safety profile
First- in human dose determination trial: used in vitro cancer cell assays to determine 1st human dose
looking at AML and lung cancer indications
phase 1 trial is underway for safety and efficacy and determine phase 2 dose
survivin has very few mutations so they are not worried about a changing epitope of their target TCR peptide of choice

The discovery of TNO155: A first in class SHP2 inhibitor

Matthew J. LaMarche
Novartis @Novartis

SHP2 is an intracellular phosphatase that is upstream of MEK ERK pathway; has an SH2 domain and PTP domain
knockdown of SHP2 inhibits tumor growth and colony formation in soft agar
55 TKIs there are very little phosphatase inhibitors; difficult to target the active catalytic site; inhibitors can be oxidized at the active site; so they tried to target the two domains and developed an allosteric inhibitor at binding site where three domains come together and stabilize it
they produced a number of chemical scaffolds that would bind and stabilize this allosteric site
block the redox reaction by blocking the cysteine in the binding site
lead compound had phototoxicity; used SAR analysis to improve affinity and reduce phototox effects
was very difficult to balance efficacy, binding properties, and tox by adjusting stuctures
TNO155 is their lead into trials
SHP2 expressed in T cells and they find good combo with I/O with uptick of CD8 cells
TNO155 is very selective no SHP1 inhibition; SHP2 can autoinhibit itself when three domains come together and stabilize; no cross reactivity with other phosphatases
they screened 1.5 million compounds and got low hit rate so that is why they needed to chemically engineer and improve on the classes they found as near hits

Closing Remarks

Xiaojing Wang
Genentech, Inc. @genentech

Follow on Twitter at:

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

Posted in BioTechnology - Venture Creation, IP Development by LPBI Group Team, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management on February 28, 2020| Leave a Comment »

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

Author: Aviva Lev-Ari, PhD, RN

How to Value a Website or Internet Business in 2020

From: Thomas Smale <acquisitions@feinternational.com>

Reply-To: <acquisitions@feinternational.com>

Date: Thursday, February 27, 2020 at 4:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Your Guide to Buying an Online Business

Hi Aviva

Thanks for your interest in our free Guide to Buying an Online Business. Please click below to download.

Guide-to-Buying-an-Online-Business-vLQ

Guide-to-Buying-an-Online-Business-vHQ

We will be in touch in a few days to see if you have any questions!

Regards,

Thomas Smale
Founder

FE International, Inc.

www.feinternational.com

FE International Framework

Alternative Metrics for Valuing Websites Or Internet Business

Discounted Cashflow Analysis
Precedent Transactions
Earnings-Multiple
Traffic Valuation
A Multiple-Based Approach to Valuing a Website or Internet Business

Defining Profitability

Factors That Influence The Multiple: Financials, Traffic, Operations, niche, Customer base

Valuation Multiples In Practice

Image source:

https://feinternational.com/blog/how-do-you-value-an-online-business/

Consider the Current Business Model

How to Value a SaaS Business

How to Value an E-Commerce Business

How to Value an App

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

On 2/27/2020 5:30AM – Aviva Wrote:

This is an excellent article.

It is very applicable for

1. Travel Websites

2. eCommerce transaction sites

3. Content: chiefly NEWS

CLAIMER:

Our PharmaceuticalIntellugence.com

A. Is an Internet based Business of Digital Content

B. Unlike 1,2,3 –

B.1 EVERY CURATION in the Journal

has content with INTRINSIC value in the form of IP belonging to the Curator’s Expertise

B.2 ALL 16 Volumes in the BioMed e-Series represent an ORIGINAL electronic Table of Contents eTOCs designed by a very unique Editor(s).

B.2.1 The evolution of the eTOCs takes many iterations among the editors AND only the Editor-in-Chief after requests for substantial alterations, usually ADD new content, declares “This is the final eTOCs for Series X, Volume Y.

(These alterations AUGMENT the IP embedded in the eTOCs design)

Example:

Genomics Volume 2: there were three iterations of eTOCs between Prof. Feldman and Aviva, first dated 2016.

In 2019,

• Aviva created single handedly the FINAL version of eTOCs and

• commissioned ALL scientists to populated Parts 7 and 8 with new content not in existence in the Journal.

• made Part 3: AI in Medicine

• made Part 4: Single Cell Sequencing

• obtained from Part 5: Evolution & Genomics from Prof. Feldman as an original curations WRITTEN for this Volume

THAT IS INTRINSIC VALUE DERIVED FROM EXPERTISE and it defines the QUALITY of this book, which is not measured by traffic. Advertisement of the book could drive page downloads and book sales. It can be done ANY TIME because each article in the book is updated in perpetuity !! A feature of our BioMed e-Series.

Does the DCF model capture the value of NON-perishable content in our Jornal and Books – no it does not

It will be valued at PREMIUM an acquirer who is sensitive to content obsolescence !!!!!

B.2.2 Page downloading will be updated for 4/19/2020

C. eProceedings are generated by Experts and the TWEET Collections carry the favorable Tweet Analytics that we presented:

• HIGH engagement,

• HIGHEST ratio tweet/likes in the Industry

• Ranked 2nd, 3rd, 4th in TOP 10 Influencers at #1 Conference in AI in Medicine in the World, 4/2019

HOW THUS VALUATION article calling for 2 to 4.5 multiplier is to capture LPBI’s

1. ECONOMIC intrinsic value on non perishable content

2. Top Expertise

3. electronic Reputation and other INTANGIBLE ASSETS as VALUE DRIVERS

FE International’s model has only LIMITED applicability to valuation of LPBI Portfolio of Intellectual Property.

Our venture shares several industries, we have identified 12 economic segments where an acquirer can be identified. The content created using the methodology of curation of scientific findings with clinical interpretation by experts was developed in house to mitigate the information explosion in the Life Sciences and the information obsolescence. The content lands its attribution to electronic Scientific Publishing and to Pharmaceutical Media. Please review the business functions that this content could contribute to by the value drivers in each economic segment https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

Introduction to Three Intellectual Property Asset Classes of Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

http://pharmaceuticalintelligence.com

LPBI Scientific Journal: 1.7Million eReaders, 5700 scientific articles [Pharmaceutics, Life Sciences, Medicine], 690 categories of research, 10,154Tags

https://lnkd.in/eEw5q7N

BioMed e-Series: 16 Volumes in Medicine and Life Sciences

https://lnkd.in/ekWGNqA

e-Proceedings: Corpus of +70 Biotech & Medical Conferences, events covered in real time by a methodology developed in house yielding the e-Proceeding with one click at the end of the Conference.

https://lnkd.in/dc2qGAK

OTHER ASSETS

Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations

Asset Class V is a Gallery of ~5000 images used in the articles and books

Asset Class VI is the Team of Experts.

Asset Class VII: Royalties on BioMed e-Series

2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020

Posted in BioTechnology - Venture Creation, Conference Coverage with Social Media on February 21, 2020| Leave a Comment »

2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020

Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover this event in REAL TIME

for

http://pharmaceuticalintelligence.com

by

@pharma_BI @AVIVA1950 @MassBio

https://events.bizzabo.com/231443

Wed Aug 26

9:30 AM

9:30 AM – 10:00 AM EDT (30 Min)

Main Stage: Welcome & Changing the Narrative Panel

10:00 AM

10:00 AM – 11:15 AM EDT (1 Hour, 15 Min)

Mike Nikitas

Master of Ceremonies

Moderator

How the message form Patient is to be shared to get the impact deserved
How do we tell the stories
1/2 or 1/3 would get the Vaccine if it is available NOW

Robert Coughlin

President and Chief Executive Officer

David Lucchino – CEO Frequency Therapeutics Mentor to Robert Coughlin – had two years of record success

MassBio

Speaker

David Lucchino

MassBio’s Immediate Past Board Chair and Co-founder, President and Chief Executive Officer

Frequency Therapeutics

Cancer survival [Millenium & Takeda drug prolonging life for Multiple Myeloma], Therapeutics developer, CEO in Biotech and President and Chief Executive Officer, MassBio
High performance students from suburban school were recruited to get opportunities in biotech

Speaker

Charles Wilson

MassBio’s Board Chair and President and Chief Executive Officer

Unum Therapeutics

Incoming MassBio’s Board Chair and President
Sustainability and opportunities
Fight COVID-19, develop Vaccines
Infrastructure to increase productivity
Equity, diversity inclusion in Biotech

Speaker

Nancy Simonian

Chief Executive Officer

Syros Pharmaceuticals, Inc.

Patient stories and journey that illness is impacting
Joining Pharma because you want to help other people
Foundation need to tell the stories for credibility vs. Pharma as drug developers or Physicians who have a skin in the game of diagnosis and treatment
1st dose of Vaccine 56% while 1/3% Black – will get the vaccine while the black has a disproportional % of COVID-19 effects
Leaders role: National, State level – people will follow Leaders
Dr. Faucci – a role model and treasure
The Focus and opportunities are in Innovations – are insafficient redirect to resonate to People on the Street – open communicate and access

Panelist

Pam Randhawa

Chief Executive Officer

Empiriko

Panelist

drug developers need to have stories from Patients about efficacy of the drug
diagnosis & treatment – tell the story
improve productivity via therapeutics – bringing ill patients back to the labor market impact on Society as a whole
Price and profiting discussion need to change to the good produced
Talking about success is not selling, involve patients to tell stories
Providers need to tell the story of patients – how they perform under a certain treatment
Quit Smoking – brought good stories and the journey of change in life style – dissemination of stories
Vaccines: Speed is increased by operation technology by Government investment – happened due to Pandemic not in regular times
Industry scaling challenge requires explanation to the Public
High health impact vs profits, yet investment needed are coming from the profits

Math needed to be done for drugs selling
Front line to bring drugs – Price too high – explain
comorbidity continues during the Pandemic – two stories need now efforts
Story: What is memorable and relatable
Leadership needs to share the stories of themselves vs talking about Financial
Talk about failing
Be careful with Vaccine to be presented as an industry issue
Strong supporter to encourge volunteers to get the Vaccine
The industry needs Solutions not winners

11:15 AM

11:15 AM – 11:30 AM EDT (15 Min)

Business Breakout: Resilience, Grit, Freedom to Fail…and Pivot

11:30 AM

11:30 AM – 12:00 PM EDT
(30 Min)

Stuart Peltz

Founder and Chief Executive Officer

PTC Therapeutics, Inc.

Moderator

Barbara Fox

Chief Executive Officer

Rheos Medicines, Inc.

Panelist

Anna Protopapas

President & Chief Executive Officer

Mersana Therapeutics, Inc.

Panelist

11:30 AM – 12:00 PM EDT
(30 Min)

Science Breakout: Lifting the Curtain on R&D to Advance New Drugs Faster

Adam Feuerstein

Senior Writer, Biotech

STAT

Moderator

Katie Ellias

Managing Director

JDRF, T1D Fund = Not-for profit on Diabetes T1D

Foundation works during the years to identify who is at risk
New avenues of Science – in development of therapies
Data sharing, Outreach to Academia
Meetings organized as an Educational day under CDA Pharma and the Foundation – Target of Exploration
What is the Foundation interested in and Pharma collaboration
Transparent with the Foundation due to under CDA
Beta cell Stress vs Stress Companies – targeting Tissue by other companies for other indication – co-develop a plan
accelerate projects to invest in therapeutics then other investors pick up
Immune response is an area of interest – Disease specific educate regulators on candidates
Manufactoring changes for COVID-19

Panelist

John Tallarico

Head, Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research

Novartis

Panelist

Gilead, Takeda and Novaris – Working together on Coronavirus on R&D aspects
Create a Journal of Negative Results – share what was tried but did not work
proprietary targets are under greatest secrecy at Novartis
Novartis Global Scholar Program – Select Academic Institutions for Tech Licensing
Collated from across all parts of Novaris – THIS IS THE PLAY BOOK for the Future and Academis Instituions share with they researches and they submit Intent to collaborate
Can the collaboration for COVID-19 can be ported to OTHER areas of research – attempts will be done because it is rewarding
COVID-19 helped transfer reagents across organization beyond COVID-19 – Silos will remain due to IP channels requiring strict protection
What emerged with OCVID-19 will be preserved vs adandoned like after SAR in 2004

12:00 PM

12:00 PM – 12:15 PM EDT
(15 Min)

Facilitated Networking: Lifting the Curtain on R&D to Advance New Drugs Faster Breakout

BROADCAST

Starts 2 min before the session time

12:00 PM – 12:15 PM EDT
(15 Min)

Facilitated Networking: Resilience, Grit, Freedom to Fail…and Pivot Breakout Session

BROADCAST

Starts 2 min before the session time

12:15 PM

12:15 PM – 12:25 PM EDT (10 Min)

Main Stage: Henri A. Termeer Innovative Leadership Award Presentation

Robert Coughlin

President and Chief Executive Officer

MassBio

Abbie Celniker

Partner

Third Rock Ventures

12:25 PM

Opportunity to innovate
Innovation in Making Therapies
Ex-Genentech –>> Millenium –> Takeda
Mounting the Antibodies response by drugs
1994 in Boston at GI – Genetic Institute – Hemophilia drugs developed – prophylactic treatment
2007 Rock Ventures to see investment in Therapeutics – building teams with diversity is the challenge – expend the landscape to diverse background
Henri A. Termeer created access to diverse work force
This Award calls for taking risks

12:25 PM – 12:45 PM EDT (20 Min)

Main Stage: Possible Talk: Patient Stories – Lina Rebeiz’s Road to Medical School

12:45 PM

12:45 PM – 1:00 PM EDT (15 Min)

Diagnosis of Acute Intermittent Porphyria (AIP) – is a rare metabolic disorder that is characterized by partial deficiency of the enzyme hydroxymethylbilane synthase (also known as porphobilinogen deaminase). This enzyme deficiency can result in the accumulation of porphyrin precursors in the body.

Lina Rebeiz

First Year Medical Student

1:00 PM

1:00 PM – 1:30 PM EDT
(30 Min)

Business Breakout: From Seed to Series A – Creative Ways to Fun Your Startup

Deborah Palestrant

Partner

5AM Ventures

Moderator

Raymond J. Tesi

President and Chief Executive Officer

ImmuneBio

Panelist

Stephen Kennedy Smith

Principal

Park Agency – Kennedy Enterprises

Panelist

1:00 PM – 1:30 PM EDT
(30 Min)

Science Breakout: Realities of Precision Medicine – How Small is Too Small?

Jennifer Carter

Healthcare Executive, Board member and Entrepreneur

JLC Precision Health Strategies, LLC

Moderator

Rare diseases are different than Cancer – is the kinase different
There are rare cancers
How small is too small

Timothy Yu

Assistant Professor in Pediatrics

Harvard Medical School

Panelist

Neurologist in Genetics department of Children’s Hospital
Rare genetic disorders without Cancer
Genetically subcategorize patients like doing so in a pediatric disease sub-population
A drug was developed for ONE single patient
Nucleotide drugs allow using one platform for several genetics disorders: Same chemical class arranged differently suite of drugs the PK and PD is similar – common approach to treat different patients with same disease but in need for drugs that as slightly different in molecular arrangement
Same drug for multiple indications vs One disease with multiple specific drugs – multiple agents in ONE drug
the only way to make progress in rare disease
EGFR a case for Genetic disease treated by drugs dealing with the genetic disorder
Duchenne is another example EXON 51 vs CRISPR
N-of-1 is the standard achievable if Regulatory will join

Marion Dorsch

Chief Scientific Officer

Blueprint Medicines

Panelist

Rare disease drug — GI 500 patients – FDA allows approval & use after Phase 1
Pediatric population vs Adult
Target the genetic driver
Few hundreds is the current goal

1:30 PM

1:30 PM – 1:45 PM EDT
(15 Min)

Facilitated Networking: From Seed to Series A – Creative Ways to Fun Your Startup

BROADCAST

Starts 2 min before the session time

1:30 PM – 1:45 PM EDT
(15 Min)

Facilitated Networking: Realities of Precision Medicine – How Small is Too Small?

BROADCAST

Starts 2 min before the session time

1:45 PM

1:45 PM – 2:02 PM EDT (17 Min)

Main Stage: Possible Talk: Steve Burton, Determination Through Adversity

Steve Burton

Sports Anchor and Reporter

WBZ-TV

Speaker

Thu Aug 27

9:30 AM

9:30 AM – 10:00 AM EDT (30 Min)

Main Stage: Possible Talk: Empowering the Financial Lives of People & Companies with Morgan Stanley

10:00 AM

10:00 AM – 10:15 AM EDT (15 Min)

David Lacchino – is praised by MassBio and Executive Team
Encourage diversity, risk taking, affects people and management
as cancer survivor did inspired Frequency Therapeutics
Thanking him for high Bar, impacting patients around the Globe

Jed Finn

Head of Corporate and Institutional Solutions; COO, Wealth Management

Morgan Stanley

Speaker

10:15 AM

Morgan Stanley (MS) – growth faster of peers $50Trillion Asset in Management +$1MM age +50 years old – Emerging segment – moving from Branch to online – direct to client – did not yet developed
In the institutional space – Siliant was acquired a SW cloud-based Canadian for combined Employers and Employees
Education, Retirement Readiness and Wealth Management for Employees via endorsement from Employers
MS offers services to biotech

MS @ works

Benefits for Employers: The C-Suite AND all other employees, lowest fees, Portal soon to be released – How many of the Employees are selleing are holding are buying, shares hold by Employees
Benefits for Employees – Individual Holdings, account reviews and Consulting offered to Employees, Financial Wellness Program to be provided by the Employer is desired by Employees

10:15 AM – 10:45 AM EDT
(30 Min)

Business Breakout: Supporting Regional Growth of the Life Sciences Beyond Cambridge

Mathias Cousin

Managing Director

Deloitte

Moderator

Jim Glasheen

Executive Vice Chancellor

University of Massachusetts Medical School

Panelist

Matt Daniels

Executive Managing Director

JLL

Panelist

10:15 AM – 10:45 AM EDT
(30 Min)

Science Breakout: AI and Drug Discovery: Marrying Data Science with Core Biology

Colin Hill

Chief Executive Officer, President, Chairman, and Co-Founder

GNS Healthcare

Moderator

cellular phynotype, drug target and therapeutics outcome
data is most important technology and Biology which has many interpretations done by different biologists
computer models need one interpretation vs many: Yes no rule bases are needed

Juan Alvarez

AVP, Computational and Structural Chemistry

Merck & Co., Inc.

Panelist

Drug Target identification
Drug Discovery – ML since 1980s
Identify molecules
syntesis prediction
physico space – physiological systems – Transcriptomics, single cell biomarkers, proteomic, metabolomics
evolving proteins
analyzing data
access to compute power data acquisition and storage – High dimensional spaces sample comparison
Find therapies for Humans in the absence of having Humans participating, data on human is BIASED by drugs history
Drugable – identify interventions translatable to Humans pathway-based
Pessimist: Unknowns and changes are inevitable
COVID-19 – some problems can be solved, some are changing environment
collect specimens from melanoma easier than from others

Renée Deehan-Kenney

PhD, VP, QuartzBio

Precision Medicine Group

Panelist

technology enable company clinical data analysis of data clical trials
ML prior knowledge
network biology
drive inside
MOA prioritize indications
Chemistry in developing drugs is complex
Network biology modeling – helps inform chemistry models: Cell line in Mice translation to Human in pancreatic cancer cell line
Pessimistic view: Long way to go end point most of the time are not good, not in my life time
must try encoouraged by published data
love basic research not in Academe

Nora Khaldi

Founder and CSO

Nuritas

Panelist

Math, computer Science
PhD in Drug discovery
Molecular chemistry of Peptide are not used in drug design
integrate toxicity, bioavailability and cell penetration of many peptides,
Identify peptides with very good PK
modulating pathways human perspective vs animal studies – no public sources on humans at the peptide level
synthetic version of plant & food vs natural version for human – efficacy it will have
AI biological data is early while relying on that knowledge
identify drug safe for human is possible I believe AI – take a molecule to humans 99% working in humans AI teated and validated in vitro

10:45 AM

10:45 AM – 11:00 AM EDT
(15 Min)

Facilitated Networking: AI and Drug Discovery: Marrying Data Science with Core Biology

10:45 AM – 11:00 AM EDT
(15 Min)

Facilitated Networking: Supporting Regional Growth of the Life Sciences Beyond Cambridge

11:00 AM

11:00 AM – 11:30 AM EDT (30 Min)

Main Stage: Possible Talk: The Process of Turning What Ifs into Realities through the Life Sciences & State of Possible Award Presentation

Judy Luu

Student

UMass Amherst

Speaker

Robert Coughlin

President and Chief Executive Officer

MassBio

Speaker

Kenneth Anderson

Director, Jerome Lipper Multiple Myeloma Center

Dana-Farber Cancer Institute

Speaker

Multiple Myeloma – 23 drugs approved by FDA
Dana-Farber Cancer Institute with Sanofi collaboration
Foundations stepped forward to study Multiple Myeloma
FDA motivated to help patients Hematologic Division – African Americans
Change paradigm of clinical trials
Geraldine Feraro was a patient at DFCI
Tom Bracow was a patient at DFCI
Ronald Burden – sports
STEM – girls 6th grade to 12 grade
David Lacchino – patient at DFCI

Joe Malarney

Complex Manager and Managing Director

Morgan Stanley

Speaker

11:30 AM

11:30 AM – 12:00 PM EDT (30 Min)

Main Stage: Building a Digital Health Community in Massachusetts and Keynote

12:00 PM

12:00 PM – 1:20 PM EDT (1 Hour, 20 Min)

Speakers

Naomi Fried

Founder and Chief Executive Officer

Health Innovation Strategies

Moderator

MA best Hospitals: MGH-BWH, Beth Israel-Lahey Clinic, Stuart
BC/BS
Medical Schools
Clusters in Biotech & Digital Health Counsel
Definition of Community changed in the COVID-19 Era
connected is having a new meaning
Service providers will play in building DIGITAL Communities

Stephen Bernstein

Attorney at Law

McDermott Will & Emery LLP

Panelist

Webinars and Zooms allows communication – we will see more innovations – Flatten the World
Greater isolation – US is expected to lead
collaborate is NOW home based – no travel – be creative
Virtual Clinical Trials
Virtual Bench science
Life sciences Products; Deploying a compound, provider responsible for the cost or how the Reimbursement will work
Consumer & Patients: Specialty Pharmacy
collaborations by planning ahead
Virtual will be inevitable if more social distancing will take place

Nick Dougherty

Managing Director

MassChallenge HealthTech

Panelist

Around the World communities, MA Biotech infrastructure
MassChallenge HealthTech: In Mexico, in Israel in Switzerland
Becoming virtual instantly in MARCH 2020
More locations pick up and scale up innovations around the Globe
Financial constraints, solve old problems

Thomas McCourt

President

Ironwood Pharmaceuticals, Inc.

Panelist

GI disease in Patients – My Gi Health started in NIH – symptoms of GI diseases
GI entrepreneurs to build a smart e-Tool to analyze the GI Symptoms
few thousand Patients
Clinical trials many are STUCK – solve problems calls for adoption of all companies to digital platforms
Entrepreneurial spirit in Kendall square took away the prime position of CA Biotech

12:45 PM – 1:05 PM EDT (20 Min)

Main Stage: Keynote: Leading in 21st Century Technologies: Our Products and Our People and Closing Remarks

BROADCAST

Starts 2 min before the session time

Susan Hockfield

President Emerita

Massachusetts Institute of Technology

Keynote

Regional advantage: Collaborations among industry and academia.
Biotech – emerging technologies cusp: Biology convergence with Engineering: sweetspot
resources to be used more productively: Opportunities to include supremely talented people
MA lead by people, by products : Digital Technologies: Physics & Engineering 1.0 to build devices: Electronics industry
21st Century: Partless Biology – DNA, RNA: Biology and Engineering 2.0 Pathways, water,
2.0 Technologies for Diagnostics for COVID-19: is frustrating
Healthcare Cost: Diagnostics too late and too expensively treated
Convergence technology in Cancer: Diagnosis is still two late: Synthetic Biomarkers: Disease specifics enzymes in nano particles used in diagnosis of cancer cells – urine based Test for cancer
Inhaling of particles Volatile organic nano particles can be exhaled for the diagnosis
Future Founders Initiative: Data, Approaches, Implementation
MIT Faculty founding of companies: 56 companies only 2 founded by Women: Inclusion of Women and Black impact GDP and innovations
Bootcamp for Women from the Lab to the Market place
Funding start ups: For Women founded and more women on boards increased to 25% signed by VC Association to track
Draw on more of our TALENTED people as advantages to be drown in the action to invent a better future

Mike Nikitas

Master of Ceremonies

Speaker

Robert Coughlin

President and Chief Executive Officer

MassBio

Speaker

youngstartup.com/vcglobal

youngStartup Ventures “Where Innovation Meets Capital” – First Round of VC Firms Announced, August 4th – 6th, 2020.

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on December 17, 2019| Leave a Comment »

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is pleased to invite you to youngStartup Ventures “Where Innovation Meets Capital” – First Round of VC Firms Announced, August 4th – 6th, 2020.

First Round of VC Firms Announced

Second Virtual Summit to feature over 100 VCs

Friends,

We’re pleased to announce the first round of VCs confirmed to be featured at Venture Summit Virtual Connect | Global being held on August 4^th – 6^th, 2020.

This exclusive venture summit will bring together over 1,300 VCs, corporate VCs, angel investors, industry executives, and founders of venture-backed, emerging, and early-stage companies, will feature more than 100 leading VCs, presentations by 100 cutting-edge innovators, and high-level networking opportunities.

Submit your company for the opportunity to present to leading investors: Click here

Connect with leading early stage VCs

Susan Akbarpour

Partner

Candou Ventures

Sep Alavi

Venture Partner

White Star Capital

Grant Allen

General Partner

Schneider Electric Ventures

Logan Allin

General Partner

Fin Venture Capital

Milad Alucozai

Partner

Good AI Capital

Amolak Badesha

Investor

Sand Hill Angels

Wade Bitaraf

Founder, Energy & Sustainability

Plug & Play Tech Center

Greg Bohlen

Managing Director

Union Grove Venture Partners

Christophe Bourque

General Partner

White Star Capital

Daniel Burstein

Managing Partner

Millennium Technology Value Partners

Adam Carson

Operating Partner

Point72 Ventures

Jeffrey Cherry

Co-Founder & Executive Director

Conscious Venture Lab

Elizabeth Cho-Fertikh

Cofounder & Managing Director

MEDA Angels

Andy Clapp

Managing Partner

Arctaris Capital Partners

Jay Crone

Director, Investments

TELUS Ventures

Lake Dai

Partner

LDV Partners

Angelo Del Priore

Partner

HP Tech Ventures

Jun Deng

Investment Partner

Joyance Partners

Robert Dunkle

Founder and CEO

ABES Venture Partners

Amy Dyck

Associate

Framework Venture Partners

Nick Efstratis

Managing Director

EPIC Ventures

Mark Farrell

Managing Director

Thayer Ventures

Andrew Felbinger

Investor

Urban Innovation Fund

Constance Freedman

Managing Partner

Moderne Ventures

Isabelle Freidheim

Managing Partner

Starwood VC

Stan Fung

Managing Director

FarSight Ventures

Norm Gitis

Managing Partner

Lymo Ventures

Ajay Gopal

Principal

Framework Venture Partners

Robert Hamlin

Principal

Portag3 Ventures

Florian Haupt

Partner

TruVenturo

Ben Jen

Investor

Ben Jen Holdings

Najib Khouri-Haddad

General Partner

Sway Ventures

Ryan Kole

Partner

VCapital

Elaine Kunda

Founder, Managing Director

Disruption Ventures

Eddie Lee

Principal

White Star Capital

James Lee

Director

Photon Fund Venture Capital

Jessica Li

Investor

Soma Capital

Ephraim Lindenbaum

Managing Director

Advance Ventures

Darwin Ling

Founding General Partner

Good AI Capital

Edwin Loredo

Vice President

Core Innovation Capital

Wasim Malik

Managing Partner

Iaso Ventures

Eugene Malobrodsky

Venture Partner

One Way Ventures

Eric Martineau-Fortin

Co-Founder and Managing Partner

White Star Capital

Philip Mertens

Associate

DSM Venturing

Ivan Nikkhoo

Managing Partner

Navigate Ventures

Carlos Ochoa

Managing Partner

AI8 VENTURES

Valerie Photos

Operating Partner

Iaso Ventures

Filipe Portela

Managing Partner

COREangels Atlantic

Safa Rashtchy

Managing Director

Think + Ventures

John Ricci

Managing Director

US Angels

Alex Rozenfeld

Managing Director

Climate Impact Capital

Gayatri Sarkar

Managing Partner

Hype Capital VC Fund

Brian Schuman

Investment Professional

PepsiCo Technology Ventures

Kristina Serafim

Managing Director

Verizon Ventures

Greg Shepard

Managing Partner

BOSS Capital Partners

Charles Sidman

Managing Partner

ECS Capital Partners

Sean Simpson

Director

WIND Ventures

Jean Sini

General Partner

Partech

Mark A. Solovy

Managing Director

Monroe Capital

Vivek Soni

General Partner

S Cap Cleantech Fund

Kat Utecht

Managing Partner

Core Innovation Capital

Jordan Wahbeh

Managing Partner

SV Venture Group

Henry Wong

Managing Partner

Diamond Tech Ventures

Stephanie Zepeda

Senior Associate

Arbor Ventures

We’re just getting started, more to be announced!

CALL FOR

TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

A select group of more than 100 Top Innovators from the fintech, technology, clean-tech, life sciences/healthcare, medical devices, healthcare IT, and mobile sectors will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners!

First Round Submission Deadline for presenting company applications is TODAY June 11^th, 2020.

To apply, your company must be privately held and ideally come from one of the following industry sectors:

Tech

Life Sciences / Healthcare

CleanTech

FinTech

EdTech

Hardware

Internet/Digital Media

IoT

Mobile

Security

Software/IT

Biotech

Diagnostics

Drug Discovery

Healthcare IT

Medical Devices

Pharma

Energy Efficiency

Energy Generation

Energy Infrastructure

Energy Storage

Transportation

Water & Wastewater

Banking

Blockchain

Insurtech

Personal Finance

Payments

Predictive Analytics

Questions about presenting? Email Preston Michaels at iwant2present (at) youngstartup .co

Seed Stage Track

If you are a seed-stage company seeking angel funding and would like to present check out our seed stage track.

If you’re seeking less than $1M (and have raised less than $300,000) this is for you.

Joe Benjamin

Founder & CEO

youngStartup Ventures

“Where Innovation Meets Capital”

Don’t hesitate to connect with me personally via LinkedIn and request to join our venture network LinkedIn group below.

August 4-6, 2020

Contact

info@youngstartup.co

212.202.1002

@@@@@

Save 20% with discount code LPBI-VIP

NEW DATE

May 5 – 7, 2020

UPDATED on 4/21/2020

Leaders in Pharmaceutical Business Intelligence (LPBI) Group invites you to join leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect being held on May 5^th– 7^th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze Register here today to confirm your spot: http://bit.ly/2PfsbM7 35% off with Discount Code: LPBI-VIP. #StayHomeSaveLives

Whether you are an investor seeking access to new early stage deals, or a CEO or Founder of a new venture looking for funding, visibility and growth, Venture Summit | Virtual Connect is one event you won’t want to miss.

Twitter

Join leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect being held on May 5^th– 7^th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze. Register here today to confirm your spot: http://bit.ly/2PfsbM7 35% off with Discount Code: LPBI-VIP. #StayHomeSaveLives

Where do #startups connect with leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators? #VSVC Venture Summit | Virtual Connect being held on May 5^th– 7^th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze. Register at http://bit.ly/2PfsbM7 and get 35% off with Discount Code: LPBI-VIP. #StayHomeSaveLives

Facebook

Leaders in Pharmaceutical Business Intelligence (LPBI) Group invites you to join leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect being held on May 5^th– 7^th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze. Register here today to confirm your spot: http://bit.ly/2PfsbM7 35% off with Discount Code: LPBI-VIP. #StayHomeSaveLives

@@@@

Venture Summit \ Virtual Connect

Where Innovation Meets Capital

May 5 – 7, 2020

Join early stage VCs, Corporate VCs, Angel Investors and founders of venture backed, emerging and early stage companies at Venture Summit \ Virtual Connect on May 5-7 2020.

Whether you’re a startup seeking capital and exposure, or an investor seeking new deals, Venture Summit \ Virtual Connect is one event you won’t want to miss.

A highly productive venture conference, Venture Summit \ Virtual Connect will feature:

Over 100 VCs (regional and national)
Presentations by 100 Top Innovators
One-on-One (zoom) investor + startup meetings
2 days of content including timely panel discussions and workshops
Keynote: Uri Levine, co-founder of Waze

Special Offer:

Leaders in Pharmaceutical Business Intelligence (LPBI) Group has made special arrangement for our network to receive 20% off with discount code LPBI-VIP (Note: Rates will go up this Thursday at midnight but the discount will still apply).

Register Today & Save Click here http://bit.ly/2PfsbM7.

Over 100 Investors Confirmed:

11.2 Capital, 500 Startups, ABES Venture Partners, Activate Capital, Advance Ventures, Aligned Partners, Alliance of Angels, Alliance Ventures, Alpha Square Group, American Family Ventures, AMINO Capital, Anzu Partners, Arbor Ventures, ARIE Capital, Asset Management Ventures, Augment Ventures, Avestria Ventures, BAM Ventures, Band of Angels, Bay Angels, Bee Partners, Ben Jen Holdings, Benhamou Global Ventures, Better Ventures, Blue Bear Capital, Blue Bear Ventures, Blue Startups, BlueRun Ventures, Boehringer Ingelheim Venture Fund, Boeing HorizonX Ventures, Brand New Matter, Candou Ventures , Catapult VC, Charles River Ventures, CIG CAP, Citi Ventures, City Light Capital, Clean Energy Venture Group, Communitas Capital Partners, Core Innovation Capital, COREangels Atlantic, Costanoa Ventures, Cottonwood Technology Fund, CRCM Ventures, Crestlight Ventures, Data Collective, Deutsche Telekom Capital Partners, DHVC, DigitalDX Ventures, Disruption Ventures, Dow Ventures, DPH Ventures, DSM Venturing, DXA Investments, Dynamk Capital, E. ON , E8 Angels, ECS Capital Partners, Elevate Ventures, Energy Foundry, Energy Innovation Capital, ENGIE New Ventures, Eudemian Ventures, Evok Innovations, F-Prime Capital, Fidelity Investments, Financial Venture Studio, FinSight Ventures, Fort Ross Ventures, Foundation Capital, Framework Venture Partners, Galaxy Digital, Garage Technology Ventures, GM Ventures, Good AI Capital, Good Growth Capital, H.I.G. Growth Partners, Halogen Ventures, Harvard Business School Angels, HealthTech Capital, Henkel Ventures, HP Tech Ventures, Hype Capital VC Fund, Insight Partners, JetBlue Technology Ventures, Johnson & Johnson Innovation – JJDC, Journey Venture Partners, Joyance Partners, Juniper Networks, K5 Ventures, Kubera Venture Capital, Lam Capital, Life Science Angels, Lymo Ventures, Magnet Ventures, ManchesterStory Group, Marcy Venture Partners, McKesson Ventures, Mighty Capital, Millennium Technology Value Partners, Moderne Ventures, Morpheus Ventures, Munich Re Ventures, MVM Partners, National Science Foundation, Navigate Ventures, NEA, New Science Ventures, New York Life Ventures, NextGen Venture Partners, NextWorld Capital, Nielsen Innovate, OCA Ventures, One Way Ventures, Owl Ventures, Pangaea Ventures, Paypal Ventures, Photon Fund, Pipeline Angels, Plug & Play Tech Center, Point72 Ventures, Portag3 Ventures, Portfolia, Prelude Ventures, PROOF VC, Revel Partners, SABIC Ventures, Samsung Catalyst Fund, Sand Hill Angels, Santander InnoVentures, Saudi Angel Fund, Shasta Ventures, SignalFire, Social Impact Capital, Spike Ventures, Starwood VC, Sunrise Capital Partners, Sway Ventures, Tech Coast Angels, The Westly Group, TiE Angels, TruVenturo, UL Ventures, Union Grove Venture Partners, Unusual Ventures, US Angels, Verizon Ventures, Viridian Capital, VisionPassage, Volvo Cars Tech Fund, WAVE Equity Partners, Wharton Alumni Angels More to be announced.

More details: http://bit.ly/2PfsbM7

We look forward to seeing you there.

Leaders in Pharmaceutical Business Intelligence (LPBI) Group & youngStartup Ventures

OLD CONTENT

NEW DATE Venture Summit | West – “Where Innovation Meets Capital”, May 5 – 7, 2020,

Santa Clara Convention Center, Silicon Valley

VSW20 – Discount code, LPBI-VIP and unique event site link http://bit.ly/2PfsbM7.

Video link for most recent event http://bit.ly/2LQpONN

UPDATED on 3/25/2020

The dedicated discount code LPBI-VIP and unique event site link http://bit.ly/2PfsbM7 now entitles LPBI network to $350 off the current rates. Applicants should register as soon as possible to lock in the lowest possible rates.

We will be hosting 1on1 startup and investor meetings live at Venture Summit | West [digital edition] online in May. The summit will now be expanded for featured companies to 3 days, May 5^th – 7^th (coaching session + 2 days of content and one on one sessions) and for general attendees to 2 days.

The summit will feature over 150 venture funds as speakers/judges (many others in attendance), more than 100 Top Innovators as presenters, effective and seamless 1:1 meetings + chat, and high-level networking opportunities.

The screening committee is currently interviewing companies and will be selecting more than 100 Top Innovators to present live to the investors at the summit.

Featured Confirmed VC Speakers & Judges:

	Kira Noodleman Bee Partners

	Kira enjoys tackling problems in disruptive industries and across cultures. Her appreciation for skillful risk-taking attracted her to entrepreneurship, and ultimately to her role in venture capital. At Bee Partners, she spends the majority of her time identifying and investing in Founders and startups servicing enterprises and enabling new marketplaces. She dedicate the remainder of […] Read more
	Li Sun Foundation Capital

	Li Sun comes from a global background spanning four countries with diverse experiences across engineering, science, technology, and entrepreneurship. She holds a B.Eng in EE and business (1st class honors) from NTU in Singapore, an M.Eng in Materials Science from MIT, and a PhD in Applied Physics from Harvard. During her PhD, she cofounded and […] Read more
	Bill Reichert Garage Technology Ventures

	Bill Reichert is co-founder and Managing Director of Garage Technology Ventures, a seed and early stage venture capital firm based in Silicon Valley. He is also a Partner at Pegasus Tech Ventures, a global venture capital firm with offices in Silicon Valley and around the world. Bill and his partners invest in promising emerging technology […] Read more
	Charlie Hanna Marcy Venture Partners

	Charlie Hanna is an investor at Marcy Venture Partners (MVP) in San Francisco, an early-stage venture capital firm co-founded by Larry Marcus, Jay Brown and Jay-Z. Charlie’s focus is consumer products and services with an emphasis on sustainability, accessibility and culture. Prior to MVP, Charlie was an Associate at SWAT Equity Partners, a NYC-based venture […] Read more
	SC Moatti Mighty Capital

	SC Moatti is the managing partner of Mighty Capital, a Silicon Valley venture capital firm, and Products That Count, one of the largest communities of product managers, leaders and entrepreneurs in the world. Previously, she built products that billions of people use at Facebook, Nokia and Electronic Arts. She also serves on boards of both […] Read more
	Mario Ruiz Paypal Ventures

	Mario Ruiz is a financial technology investor at PayPal Ventures, focusing on investments in the U.S. and internationally. Prior to joining PayPal, Mario was an investor at Napier Park, where he was a member of a nine-person investment team responsible for the evaluation, diligence, and execution of growth equity and real asset investments. Mario started […] Read more
	Danny Cotter The Westly Group

	Danny Cotter serves as Principal at The Westly Group. Prior to joining the Westly Group, He worked at Pacific Gas & Electric Company where he focused on discovering advanced technology pilots and analyzing regulatory, competitive and technology landscapes to shape smart grid strategies across the organization. While at PG&E, He also helped lead the development […] Read more

UPDATED on 2/26/2020

The dedicated discount code LPBI-VIP and unique event site link http://bit.ly/2PfsbM7 now entitles LPBI network to $350 off the current rates. Applicants should register as soon as possible to lock in the lowest possible rates.

Updated list of over 130 VCs and Angels confirmed to speak and judge.

Partial Lineup of over 130 VCs & Angels confirmed to speak and judge includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Andrew Abrams, Vice President, New Science Ventures | Susan Akbarpour, Partner, Candou Ventures | Joel Albarella, Founder, New York Life Ventures | Navid Alipour, Co-founder and Managing Partner, Analytics Ventures | Shaun Arora, Founding Partner, MiLA Capital | Doug Atkin, Managing Partner, Communitas Capital Partners | Shannon Austin, Partner, Financial Venture Studio | Jennifer Azapian, Partner , Mighty Capital | Mike Biddle, Managing Director, Evok Innovations | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Dave Blivin, Managing Director, Cottonwood Technology Fund | Greg Bohlen, Managing Director, Union Grove Venture Partners | Maureen Boyce, Managing Partner, Good Growth Capital | Peter Bruce-Clark, Partner, Social Impact Capital | Pratik Budhdev, Investment Director, Volvo Cars Tech Fund | Amy Burr, Managing Director, JetBlue Technology Ventures | Ray Chan, Managing Director, K5 Ventures | Ryan Chou, Investment Associate, JetBlue Technology Ventures | Darren Cooke, Investor, Life Science Angels | Martha Cosgrove, Investing Associate, Boeing HorizonX | Danny Cotter, Principal, The Westly Group | Ross Darwin, Principal, Owl Ventures | Anne DeGheest, Founder, HealthTech Capital | Angelo Del Priore, Partner, HP Tech Ventures | Jun Deng, Partner, Joyance Partners | Dan Doble, Managing Director, SABIC Ventures | Ted Driscoll, Managing Partner, DigitalDX Ventures | Robert Dunkle, President, ABES Venture Partners | Ali Farahanchi, Director, DHVC | Anna Fokina, Senior Associate, Data Collective | Isabelle Freidheim, Co-founder & Managing Partner, Starwood VC | Emily Fritze, Senior Associate, The Westly Group | Will Fung, Senior Associate, Samsung Catalyst Fund | Norm Gitis, Managing Partner, Lymo Ventures | Ajay Gopal, Founding Principal, Framework Venture Partners | Daniel Greene, Principal, Wipro Ventures | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Charlie Hanna, Investor, Marcy Venture Partners | Daniel Harris, Managing Director, DPH Ventures | Florian Haupt, Partner, TruVenturo | Guy Horowitz, Partner, Deutsche Telekom Capital Partners | Jens Horstmann, Founding Director, Crestlight Ventures | Michael Julve, Associate, 500 Startups | Najib Khouri-Haddad, General Partner, Sway Ventures | Howard Ko, Principal, Morpheus Ventures | Shruti Kothari, Director, Kaiser Permanente Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ricky Lai, Principal, Portag3 Ventures | Anh Le, Partner, CRCM Ventures | James Lee, Investment Associate Director, Photon Fund | Marina Levinson, Partner, Benhamou Global Ventures | Larry Li, Managing Partner, AMINO Capital | Darwin Ling, Founding General Partner, Good AI Capital | Catherine Lu, Managing Partner , Alumni Ventures Group (AVG) | Vincent Lui, Partner, XCEL Asia | Hector MacQuarrie, Senior Investment Associate, Shell Ventures | Radhika Malik, Investment Manager, Samsung Catalyst Fund | Ricky Margolis, VP of Business Development, ARIE Capital | Melina Mathur, Principal, Asset Management Ventures | Manan Mehta, Founding Partner, Unshackled Ventures | Eric Meyer, Vice President, Activate Capital | Jonathan Mo, Senior Associate, 11.2 Capital | SC Moatti, Managing Partner, Mighty Capital | Mark Mueller-Eberstein, Angel Investor, Alliance of Angels | Maxim Nazarov, Investor, FinSight Ventures | Ivan Nikkhoo, Managing Partner, Navigate Ventures | Kira Noodleman, Principal, Bee Partners | Brett Noyes, Founder & Managing Director, Unbank. Ventures | Demi Obayomi, Investor, NextWorld Capital | Nihar Patel, General Partner, Journey Venture Partners | Charles Paul, Vice President – Technology, Henkel Ventures | Damien Petty, Principal, Morpheus Ventures | Patrick Pfeffer, Lead Investor, Juniper Networks | Scott Pinizzotto, Senior Investment Director, ENGIE New Ventures | Bill Reichert, Managing Director, Garage Technology Ventures | Mario Ruiz, Investor, Paypal Ventures | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Gayatri Sarkar, Managing Partner, Hype Capital VC Fund | Jordan Segall, Enterprise Investor, Unusual Ventures | Kristina Serafim, Managing Director, Verizon Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Sean Simpson, Investment Manager, GM Ventures | Ratan Singh, Principal, Fort Ross Ventures | Kenn So, Associate, Shasta Ventures | Allison Steitz, Investor, BlueRun Ventures | Li Sun, Partner, Foundation Capital | Jessica Tan, Associate, 500 Startups | Grahme Taylor, Venture Analyst, Wildcat Venture Partners | Jonathan Tower, Founding Managing Partner, Catapult VC | Erica Van, Investor, Charles River Ventures | Anuj Varma, Investor, BAM Ventures | Kutral Veerabadran, Principal, Flow Capital | Alessandro Vigilante, Head of Global Innovation Ecosystem, Fidelity Investments | Sonali Vijayavargiya, Managing Director, Augment Ventures | Alex Whitney, Senior Analyst, ManchesterStory Group | Henry Wong, Managing Director, Garage Technology Ventures | Joanne Wong, General Partner, REDDS Capital | Russell Yue, Investor, H.I.G. Growth Partners | Elaine Zelby, Principal & Director of Growth, SignalFire | Stephanie Zepeda, Senior Associate, Arbor Ventures | Yanan Zhao, General Partner, Magnet Ventures | Sebastian Zhou, Investor, Alpha Square Group | Simin Zhou, VP & Managing Director, UL Ventures and many more…

UPDATED on 2/6/2020

Leaders in Pharmaceutical Business Intelligence (LPBI ) Group is pleased to spons and invite you to join us at Venture Summit | West

Special offer: Register Now & Save $450 off (Use discount code “LPBI-VIP”)

* Call for Top Innovators Details below

Venture Summit | West

Where Innovation Meets Capital

March 23^rd & 24^th 2020

Santa Clara Convention Center, Silicon Valley

Reminder to register for the prestigious Venture Summit | West being held on March 23^rd & 24^th 2019 at the Santa Clara Convention Center. This year will again feature a dedicated Lifesciences/Healthcare Track. Come meet, interact and network with more than 1,300 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies.

Whether you’re a Lifesciences/Healthcare startup seeking capital and exposure, or an investor seeking new deals, Venture Summit West presented by youngStartup Ventures – is the event of the year you won’t want to miss.

A highly productive venture conference, Venture Summit | West is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

Partial Initial Lineup of over 90 VCs & Angels confirmed to speak and judge includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Andrew Abrams, Vice President, New Science Ventures | Susan Akbarpour, Partner, Candou Ventures | Navid Alipour, Co-founder and Managing Partner, Analytics Ventures | Shaun Arora, Founding Partner, MiLA Capital | Shannon Austin, Partner, Financial Venture Studio | Jennifer Azapian, Partner , Mighty Capital | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Dave Blivin, Managing Director, Cottonwood Technology Fund | Greg Bohlen, Managing Director, Union Grove Venture Partners | Maureen Boyce, Managing Partner, Good Growth Capital | Peter Bruce-Clark, Partner, Social Impact Capital | Pratik Budhdev, Investment Director, Volvo Cars Tech Fund | Darren Cooke, Investor, Life Science Angels | Martha Cosgrove, Investing Associate, Boeing HorizonX | Danny Cotter, Principal, Westly Group | Ross Darwin, Principal, Owl Ventures | Anne DeGheest, Founder, HealthTech Capital | Jun Deng, Partner, Joyance Partners | Dan Doble, Managing Director, SABIC Ventures | Robert Dunkle, President, ABES Venture Partners | Ali Farahanchi, Director, DHVC | Anna Fokina, Senior Associate, Data Collective | Norm Gitis, Managing Partner, Lymo Ventures | Daniel Greene, Principal, Wipro Ventures | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Charlie Hanna, Investor, Marcy Venture Partners | Daniel Harris, Managing Director, DPH Ventures | Florian Haupt, Partner, TruVenturo | Guy Horowitz, Partner, Deutsche Telekom Capital Partners | Jens Horstmann, Founding Director, Crestlight Ventures | Najib Khouri-Haddad, General Partner, Sway Ventures | Howard Ko, Principal, Morpheus Ventures | Shruti Kothari, Director, Kaiser Permanente Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ricky Lai, Principal, Portag3 Ventures | Anh Le, Partner, CRCM Ventures | James Lee, Investment Associate Director, Photon Fund | Marina Levinson, Partner, Benhamou Global Ventures | Larry Li, Managing Partner, AMINO Capital | Darwin Ling, Founding General Partner, Good AI Capital | Catherine Lu, Managing Partner , Alumni Ventures Group (AVG) | Vincent Lui, Partner, XCEL Asia | Melina Mathur, Principal, Asset Management Ventures | Manan Mehta, Founding Partner, Unshackled Ventures | Eric Meyer, Vice President, Activate Capital | Jonathan Mo, Senior Associate, 11.2 Capital | SC Moatti, Managing Partner, Mighty Capital | Mark Mueller-Eberstein, Angel Investor, Alliance of Angels | Ivan Nikkhoo, Managing Partner, Navigate Ventures | Kira Noodleman, Principal, Bee Partners | Brett Noyes, Founder & Managing Director, Unbank.Ventures | Charles Paul, Vice President – Technology, Henkel Ventures | Damien Petty, Principal, Morpheus Ventures | Patrick Pfeffer, Lead Investor, Juniper Networks | Scott Pinizzotto, Senior Investment Director, ENGIE New Ventures | Bill Reichert, Managing Director, Garage Technology Ventures | Mario Ruiz, Investor, Paypal Ventures | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Gayatri Sarkar, Managing Partner, Hype Capital VC Fund | Kristina Serafim, Managing Director, Verizon Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Principal, Fort Ross Ventures | Allison Steitz, Investor, BlueRun Ventures | Li Sun, Partner, Foundation Capital | Grahme Taylor, Venture Analyst, Wildcat Venture Partners | Jonathan Tower, Founding Managing Partner, Catapult VC | Erica Van, Investor, Charles River Ventures | Anuj Varma, Investor, BAM Ventures | Kutral Veerabadran, Principal, Flow Capital | Sonali Vijayavargiya, Managing Director, Augment Ventures | Alex Whitney, Senior Analyst, ManchesterStory Group | Henry Wong, Managing Director, Garage Technology Ventures | Russell Yue, Investor, H.I.G. Growth Partners | Elaine Zelby, Principal & Director of Growth, SignalFire | Stephanie Zepeda, Senior Associate, Arbor Ventures | Yanan Zhao, General Partner, Magnet Ventures | Sebastian Zhou, Investor, Alpha Square Group | Simin Zhou, VP & Managing Director, UL Ventures and many more.

Special Offer:

LPBI has made special arrangement for our network to receive a special discount of $450 off. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

Register Today & Save Click here. (Use promo code “ LPBI-VIP”)

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

Volunteer Opportunities:

Students and recent alumni are to volunteer to help out for part of the day and enjoy the summit for the other part. Volunteers assist with setup, registration, program coordination, company presentations etc. To join us as a volunteer, please fill out the form here: Click Here http://bit.ly/VSW20VOLUNTEER .

UPDATED on 1/16/2020

Leaders in Pharmaceutical Business Intelligence (LPBI ) Group is pleased to sponsor and invite you to join us at Venture Summit | West

Special offer: Register Now & Save $450 off (Use discount code “LPBI-VIP”)

* Call for Top Innovators Details below

Venture Summit | West

Where Innovation Meets Capital

March 23^rd & 24^th 2020

Santa Clara Convention Center, Silicon Valley

Partial Initial Lineup of over 60 VCs & Angels confirmed to speak and judge includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Shaun Arora, Founding Partner, MiLA Capital | Shannon Austin, Partner, Financial Venture Studio | Jennifer Azapian, Partner , Mighty Capital | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Greg Bohlen, Managing Director, Union Grove Venture Partners | Peter Bruce-Clark, Partner, Social Impact Capital | Darren Cooke, Investor, Life Science Angels | Ross Darwin, Principal, Owl Ventures | Anne DeGheest, Founder, HealthTech Capital | Jun Deng, Partner, Joyance Partners | Robert Dunkle, President, ABES Venture Partners | Anna Fokina, Senior Associate, Data Collective | Norm Gitis, Managing Partner, Lymo Ventures | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Charlie Hanna, Investor, Marcy Venture Partners | Daniel Harris, Managing Director, DPH Ventures | Guy Horowitz, Partner, Deutsche Telekom Capital Partners | Jens Horstmann, Founding Director, Crestlight Ventures | Najib Khouri-Haddad, General Partner, Sway Ventures | Howard Ko, Principal, Morpheus Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ricky Lai, Principal, Portag3 Ventures | Anh Le, Partner, CRCM Ventures | James Lee, Investment Associate Director, Photon Fund | Darwin Ling, Founding General Partner, Good AI Capital | Melina Mathur, Principal, Asset Management Ventures | Manan Mehta, Founding Partner, Unshackled Ventures | SC Moatti, Managing Partner, Mighty Capital | Mark Mueller-Eberstein, Angel Investor, Alliance of Angels | Ivan Nikkhoo, Managing Partner, Navigate Ventures | Kira Noodleman, Principal, Bee Partners | Damien Petty, Principal, Morpheus Ventures | Patrick Pfeffer, Lead Investor, Juniper Networks | Bill Reichert, Managing Director, Garage Technology Ventures | Mario Ruiz, Investor, Paypal Ventures | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Gayatri Sarkar, Managing Partner, Hype Capital VC Fund | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Principal, Fort Ross Ventures | Li Sun, Partner, Foundation Capital | Erica Van, Investor, Charles River Ventures | Kutral Veerabadran, Principal, Flow Capital | Sonali Vijayavargiya, Managing Director, Augment Ventures | Elaine Zelby, Principal & Director of Growth, SignalFire | Stephanie Zepeda, Senior Associate, Arbor Ventures | Yanan Zhao, General Partner, Magnet Ventures | Sebastian Zhou, Investor, Alpha Square Group | Simin Zhou, VP & Managing Director, UL Ventures and many more.

Special Offer:

LPBI has made special arrangement for our network to receive a special discount of $450 off. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

Register Today & Save Click here. (Use promo code “ LPBI-VIP”)

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

We look forward to seeing you there.

LPBI & youngStartup Ventures

@@@@@@

Leaders in Pharmaceutical Business Intelligence (LPBI ) Group is pleased to announce its sponsorship and invite you to join us at Venture Summit | West

Special offer: Register Now & Save $450 off

(Use discount code “LPBI-VIP”)

* Call for Top Innovators Details below

Venture Summit | West

Where Innovation Meets Capital

March 23^rd & 24^th 2020

Santa Clara Convention Center, Silicon Valley

Come meet, interact and network with more than 1,300 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit | West being held on March 23^rd & 24^th 2019 at the Santa Clara Convention Center. This year will again feature a dedicated Lifesciences/Healthcare Track.

Lineup of over 150 VCs and Angels that spoke and judged at VSW19 includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Navid Alipour, Co-founder and Managing Partner, Analytics Ventures | Logan Allin, General Partner & Founder, Fin Venture Capital | Kareem Aly, Principal, Thomvest Ventures | Magdi Amin, Investment Partner, Omidyar Network | Ash Archibald, Deal Principal, Wharton Angels | Jennifer Azapian, Partner , Mighty Capital | Carlos S. Baradello, General Partner, Alaya Capital Partners | Scott Beechuk, Partner, Norwest Venture Partners | Marcus Behrendt, Partner, BMW i Ventures | Lisha Bell, Dealflow Lead, Pipeline Angels | Ashish Bhatia, Angel Investor | Sunny Bia, Associate, CRCM Ventures | Mike Biddle, Managing Director, Evok Innovations | Alexa Binns, Associate, Maven Ventures | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Tico Blumenthal, Co-chair of the Medical Device Screening Committee, Life Science Angels | Greg Bohlen, Managing Director, Union Grove Venture Partners | Will Borthwick, Senior Associate, Bold Capital Partners | Eric Breese, Investment Manager, Evonik Venture Capital | Maxx Bricklin, Founding Principal, Bold Capital Partners | Pratik Budhdev, Investment Director, Volvo Cars Tech Fund | Edouard Bulteau, Investment Manager, Total Energy Ventures | Andy Cao, Principal, Comcast Ventures | Packey Carrier, Investment Manager, American Express Ventures | Jeffrey Carter, General Partner, West Loop Ventures | Matthew Chavez, Associate, New Enterprise Associates | Joy Chen, Chief Investment Officer, TAL Education Group | Kelly Chen, Principal, Data Collective | Keting Chu, Venture Partner, LYFE Capital | Jackson Cummings, Investor, Salesforce Ventures | Michael D’Aurizio, Investment Manager, Centrica Innovations | Ned Daoro, Senior Associate, Clocktower Technology Ventures | Angelo Del Priore, Partner, HP Tech Ventures | Jun Deng, Partner, Joyance Partners | Dan Doble, Managing Director, SABIC Ventures | Rexhi Dollaku, Principal, Base10 | Yizhen Dong, Principal, 11.2 Capital | Ted Driscoll, Managing Partner, DigitalDX Ventures | Marah Dudenhoeffer, Manager, Verizon Ventures | Susannah Duke, Associate, Pelion Venture Partners | Robert Dunkle, President, ABES Venture Partners | Victor Echevarria, Principal, Jackson Square Ventures | Tom Eggleston, Managing Director , Charmides Capital | Geoffrey Eisenberg, Principal, Ecosystem Integrity Fund | Sean Engel, Principal, Top Tier Capital Partners | Michael Fanfant, Senior Associate, Runa Capital | Chenoa Farnsworth, Managing Director, Blue Startups | Kristen Faulkner, Associate, Threshold Ventures | Linda Fingerle, Partner, Tappan Hill Ventures | Spencer Foust, Principal, Sozo Ventures | Ben Freeberg, Senior Associate, Alpha Venture Partners | Chris Gaertner, Principal, Omega Venture Partners | Karim Gillani, General Partner, Luge Capital | Norm Gitis, Managing Partner, Life Science Angels | Garrett Goldberg, Partner, Bee Partners | Jocelyn Goldfein, Managing Director, Zetta Venture Partners | Daniel Gomez, Investment Analyst, Fusion Fund | Tyler Griffin, Managing Partner, Financial Venture Studio | Baris Guzel, Principal, BMW i Ventures | Perry Ha, Analyst, The Westly Group | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Daniel Harris, Managing Director, DPH Ventures | Laurence Hayward, Partner, Independence Equity | Annie Hazlehurst, Founder, Faridan | Alicia Castillo Holley, Investor, Sand Hill Angels | Jens Horstmann, Founding Director, Crestlight Ventures | Heyu Huang, Venture Partner, Fresco Capital | Anup Jacob, Co-Founder & Managing Director, Activate Capital Partners | Alexis Ji, Partner, Illumina Ventures | Gary Jinks, Founding Managing Director, South Valley Angels | Matt Jones, Managing Director, Solvay Ventures | Kathleen Jurman, Corporate Technology Scout, Dow Ventures | Amir Kabir, Investment Principal, Munich Re Ventures | Jimmy Kan, Senior Associate, Anzu Partners | Kester Keating, Head of US Strategic Investments, Barclays | Roger King, Founder, Bay Angels | Steve Kishi, Managing Director, Hummer Winblad Venture Partners | Yasemin Kliman, Co-President, Harvard Business School Angels | Daniella Kranjac, Co-Founder & Managing Director, Dynamk Capital | Nathan Krishnamurthy, Principal, Capital One Growth Ventures | Vivek Krishnamurthy, Associate, Commerce Ventures | Amit Kumar, Investor, Band of Angels | Kwasi Kyei, Associate, Sandbox Industries | Eduardo Laiter, Sr Investment Analyst, Kapor Capital | Severine Lalande, Investment Manager, Total Energy Ventures | Javaughn Lawrence, Investor, Eniac Ventures | Lindsay Lee, Managing Director, Authentic Ventures | Roberta Lee, Angel Investor, Life Science Angels | Sarah Lee, Investor, EdVentures Group | Julie Lein, Managing Partner, Urban Innovation Fund | Geraldine Le Meur, Founding Partner, The Refiners | Ephraim Lindenbaum, Managing Director, Advance Ventures | Alex Luce, Principal, Creative Ventures | Vincent Lui, Senior Director of Corporate Ventures, SK Telecom Americas | Silvia Mah, Executive Director and Founder, Hera Angels | Ashish Mahashabde, Investor, Amex Ventures | Shripriya Mahesh, Co-Founding Partner, Spero Ventures | Tasneem Manjra, Head of Network Development, Volvo Cars Tech Fund | Jillian Manus, Managing Partner, Structure Capital | Ben Metcalfe, Principal, Ridge Ventures | Wouter Meuleman, Director of Investments, Illumina Ventures | SC Moatti, Managing Partner, Mighty Capital | Linda Molnar, Program Director, National Science Foundation | Sasha Ostojic, Angel investor, Playground Global | Umesh Padval, Venture Partner, Thomvest Ventures | Hirak Parikh, Venture Partner, Augment Ventures | Victor Pascucci III, Managing Partner, Lightbank | Phoebe Peronto, Investor, Salesforce Ventures | Ricardo Politi, Partner, Mindset Ventures | Salil Pradhan, Venture Partner, Draper Nexus | Gagan Rana, Executive-in-Residence, Learn Capital | Peter Redford, Investor, Band of Angels | Bill Reichert, Managing Director, Garage Technology Ventures | John Ricci, Founder & Managing Partner, US Angels | Jennifer Richard, Senior Associate, Cross Culture Ventures | Andre Rocha, Investor, Glasswing Ventures | Riley Rodgers, Associate, Valia Investments | Peter Rojas, Founding Partner, Betaworks Ventures | Praveen Sahay, Managing Director, WAVE Equity Partners | Natalie Sandman, Senior Associate, Shasta Ventures | Miraj Sanghvi, Principal, DigiTx | Jason Schoettler, Co-Founder & Partner, Calibrate Ventures | Wes Selke, Managing Director, Better Ventures | Jayni Shah, Principal, Accomplice | Prashant Shah, Partner, Monta Vista Capita | Ann Shin, Founding Partner, Ultrafund Capital | Charles Sidman, Managing Partner, ECS Capital Partners | Kathleen Siswanto, Investor, Propel Venture Partners | Ira Smith, Director of Venture Investments, Pandect BioVentures | Tanya Soman, Venture Partner, 500 Startups | Shirley Speakman, Partner, Cycle Capital Management | Adam Spector, Angel Investor | Kumar Sripadam, Chair, TiE Global | Jack Statza, Senior Associate, Allstate Strategic Ventures | George Straschnov, Managing Director, Bisk Ventures | Marcus Stroud, Managing Partner, TXV Partners | Mayra Tama, Principal, Initial Capital | Wei Tao, Life Science Angels, Chair Bio Genomics Committee | Craig Taylor, General Partner, Alloy Ventures | Laura Thompson, Principal, Sapphire Ventures | Vishal Verma, General Partner, Edgewood Ventures | Che Voigt, Chairman, North Bay Angels | Jordan Wahbeh, Managing Director, Bay Angels | Timothy Wang, Principal, The Westly Group | Kyoko Watanabe, Managing Director, DEFTA Partners | Patricia Wexler, Co-Founder & Managing Director, Starlight Ventures | James Wu, Senior Associate, M12 | Jonathan Wu, Board Director and Vice President, Sand Hill Angels | Margaret Wu, Investor, Georgian Partners | Veronica Wu, Managing Partner, Hone Capital | Wei Wu, Healthcare Investment Director, BOE Ventures | Matthew Wukasch, Managing Director, Charmides Capital | Wenz Xing, Associate, Bullpen Capital | Sue Xu, Managing Partner , Amino Capital | Lu Zhang, Founder & Managing Partner, Fusion Fund | Jimmy Zhu, Vice President, Citi Ventures | Shelley Zhuang, Founder and Managing Partner, 11.2 Capital | TX Zhuo, Managing Partner, Fika Ventures and many more.

Special Offer:

LPBI has made special arrangement for our network to receive a special discount of $450 off.

This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

Register Today & Save Click here. (Use promo code “ LPBI-VIP”)

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

We look forward to seeing you there.

LPBI & youngStartup Ventures

LPBI Group – Executive Summary

The Challenge

“Today, there is a digital information explosion in the fields of Life Sciences and Medicine,” said Aviva Lev-Ari, Ph.D., R.N., and founder of Leaders in Pharmaceutical Business Intelligence (LPBI) Group. “To manage that challenge, we are responding to the needs of our multi-faceted audiences in order to guard against information obsolescence through transformational technologies and solutions.”

Our Vision:

LPBI Group generates vast scientific content via industry thought leaders through multiple platforms and makes it universally accessible.

About LPBI Group

Leaders in Pharmaceutical Business Intelligence Group (“LPBI Group”) is a leading, electronic scientific content-creation venture, offering real-time, original scientific content through advanced platform architecture methodologies since 2012. The company’s commitment is to synthesize, analyze and interpret complex, medical and scientific disease information through electronic publishing venues via the cloud to advance the knowledge and research efforts of the scientific and business community.

LPBI Group was created in 2012 by Dr. Aviva Lev-Ari, Ph.D., R.N. The Group has evolved into three, interrelated domains – an open-access online scientific journal, a series of 16 BioMed e-books and real-time press coverage of BioMed scientific and medical conferences. Through this transformative offering, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any subject as well as cutting-edge biomedical research innovation widely available to the scientific and non-research community. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.

Year over year, there is increased readership of highly valued content, which equates to more than 5,500 scientific articles with over 1.6 million readers in the online scientific journal.

Unique, Experienced Team

The Group employs a team of highly experienced individuals in Life Sciences, particularly within the key domains of BioMedicine, Biotechnology, Pharmaco-therapy, Medical and Information Technology, Health Care and the Life Sciences/Medicine connection.

All members of the LPBI Group team have a wealth of expertise and experience in Life Sciences and have been trained to master the methodology of scientific curation used in the articles. Those individuals include senior MDs, MD/PhDs, PharmDs and senior PhDs who expressed interest in medical writing and clinical interpretation of basic research, translational research and interpretation of clinical trials outcomes.

Medical Doctors: Dr. Larry H. Bernstein (retired), Dr. Justin Pearlman (Central Maine Medical Center)
Doctors of Philosophy: Dr. Justin Pearlman, Dr. Stephen Williams, Dr. Sudipta Saha, Dr. Ritu Saxena, Dr. Tilda Barliya, Dr. Irina Robu, Dr. Dror Nir, Dr. Aviva Lev-Ari
Professors in Academia: Prof. Marcus W. Feldman (Stanford University), Prof. Stephen J. Williams (Temple University), Prof. Sudipta Saha (Amity University Noida, Uttar Pradesh, India), Dr. Irina Robu (Windsor, Ontario, Canada), Adam Sonnenberg, PhD(c), Boston University
Executives in Biotechnology and Information Technology Industries: Amnon Danzig, MBA, Europe-Asia (business development consultant with specialization in Strategy, Corporate Finance and Human Capital, published author on Value Creation concepts), Rick Mandahl, MBA, Americas (business development consultant in emerging technologies with Biotech, Information Technology focus), Ritu Saxena (Astellas Pharma), Gail S. Thornton, M.A., PhD(c), (Merck & Co., USA, communications consultant, published author on health, wellness, communications strategy)

Scientific e-Books Source

The 16 BioMed e-books include topics focused on medical science, diagnostics and therapy. The books’ sustainability is maintained by online continuing updates made to articles in the online scientific journal. Each of the scientific e-books contain an abbreviated electronic table of contents, which consists of ‘live’ links from each article in the e-book to the article in the online scientific journal. Readers of the e-books can click on this link to receive the most, updated “State of Science” for each topic. This unique feature makes the e-books relevant and provides a timely source of knowledge and reference.

Highly qualified content consultants, who are senior MDs, MD/PhDs and Professors, are involved in the production and clinical interpretations of the curations. The topics for curation and the contents of the books are uniquely created and carefully edited. Dr. Aviva Lev-Ari as the editor-in-chief leads this multidisciplinary content compilation using her diverse areas of technical training and experience. It should be noted that all of LPBI’s material could, in principle, be translated into other languages.

Journal Ontology

Our intellectual property consists of three classes of Intellectual property assets as described in detail with live links in the following article:

eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model

https://pharmaceuticalintelligence.com/2019/02/04/escientific-publishing-a-case-in-point-evolution-of-platform-architecture-methodologies-and-of-intellectual-property-development-content-creation-by-curation-business-model/

Three Classes of Intellectual Property Assets

These assets include an open-access online scientific journal with curated, current biomedical research; a series of 16 BioMed e-books available via Amazon in five specialties of Medicine: Cardiovascular, Genomic Medicine (a subset of Precision Medicine), Cancer, Immunology and Precision Medicine; and real-time curation of biotech and medical conferences yielding an e-Proceedings at the end of the conference in one click operation.

For example, Genomic Medicine, as an emerging medical discipline, is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases and infectious disease. This field involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use.

The open-access online scientific journal ontology is a relational and hierarchical knowledge base allowing for expansion of the content creation process between the journal and the series of BioMed e-books, but it is not limited to these two areas. For example, one of the research categories, entitled “Interviews with Scientific Leaders,” includes in its growth plan the option of podcasts, an audio media component that will supplement the video media component used extensively in the BioMed e-Series.

The Group’s business is scalable, and the skill set needed for curation of scientific findings for clinical interpretations, as well as in other disciplines can be augmented by appropriate training in the curation methodology to be offered to experts in many fields. In our seven years together, the Group’s writers and editors generated a remarkable synergy among experts, authors and writers, which yields outstanding collaboration in producing these curations. There are many post-doctoral individuals in the biotechnology industry as well as academia who can serve as experts, authors and writers in continuing the Group’s operations, following appropriate onboarding.

Contact us

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, NJ, Salt Lake City, Berkeley, Cambridge UK, Maine, New Delhi, Palo Alto, Philadelphia, Toronto

Editor-in-Chief

http://pharmaceuticalintelligence.com

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile

https://pharmaceuticalintelligence.com/2019-vista/executive-summary/

Selection Process for Chief Innovation and Entrepreneurship Officer (CIEO) @Berkeley: Ecosystem Evangelist, Professor Richard Lyons, Berkeley’s ex-Dean of the Haas School of Business

Posted in BioTechnology - Venture Creation, Innovations, Intellectual Property, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough on July 22, 2019| Leave a Comment »

Selection Process for Chief Innovation and Entrepreneurship Officer (CIEO) @Berkeley: Ecosystem Evangelist, Professor Richard Lyons, Berkeley’s ex-Dean of the Haas School of Business

Reporter: Aviva Lev-Ari, PhD, RN, Berkeley PhD’83

for @Berkeley Alumna Ecosystem Evangelist see

The University of California at Berkeley appointed professor Richard Lyons as the university’s first-ever chief innovation and entrepreneurship officer (CIEO).

The Selection Process

Professor Richard Lyons was selected for the CIEO position through a rigorous recruitment and selection process that attracted several hundred top-notch applications from all over the world. Throughout the process, Lyons stood out as a true visionary, a strategic leader and an ecosystem evangelist who could understand and activate the untapped potential of Berkeley’s innovation and entrepreneurship landscape.

“If together we can improve the transformation of Berkeley’s prodigious intellectual product, across the whole campus, into greater societal benefit, then we will have achieved a great deal,” said Lyons, in a statement.

Image Source: Courtesy of University of California, Berkeley, Doe Library Building with the Campanile Tower in the background

Professor Richard Lyons, Accomplishments as Berkeley’s ex-Dean of the Haas School of Business

He helped launch the Management, Entrepreneurship, & Technology (M.E.T.) dual-degree program in partnership with the College of Engineering.
He also initiated the Biology + Business dual degree program with Molecular & Cell Biology and
He revitalized the Berkeley-Haas Entrepreneurship Program (BHEP).
He helped the campus to launch the Berkeley SkyDeck startup accelerator in 2012 and served on its Governing Board, did that in collaboration with leadership in the Office of Research and College of Engineering.

SOURCE

https://venturebeat-com.cdn.ampproject.org/c/s/venturebeat.com/2019/07/10/richard-lyons-will-be-uc-berkeleys-first-ever-chief-innovation-and-entrepreneurship-officer/amp/

https://www.genomeweb.com/business-news/glaxosmithkline-ucs-doudna-establish-67m-genomics-crispr-research-lab#.XQKQ8tNKgcg

Laboratory for Genomics Research (LGR) to be established by GSK ($67M investment in 5 years) at UC, Berkeley/UCSF to be lead by Prof. Jennifer Doudna focusing on immunology, oncology, and neuroscience disease-causing gene mutations and development of new technologies using CRISPR to accelerate new drug discovery

Posted in BioTechnology - Venture Creation, CRISPR/Cas9 & Gene Editing on June 13, 2019| 1 Comment »

Laboratory for Genomics Research (LGR) to be established by GSK ($67M investment in 5 years) at UC, Berkeley/UCSF to be lead by Prof. Jennifer Doudna focusing on immunology, oncology, and neuroscience disease-causing gene mutations and development of new technologies using CRISPR to accelerate new drug discovery

Reporter: Aviva Lev-Ari, PhD, RN

GlaxoSmithKline, UC’s Doudna Establish $67M Genomics, CRISPR Research Lab

Jun 13, 2019 | staff reporter

Save for later

NEW YORK (GenomeWeb) – Drug company GlaxoSmithKline announced today that it will establish a laboratory for CRISPR technologies as part of a five-year collaboration with University of California researchers.

The new Laboratory for Genomics Research (LGR) will investigate disease-causing gene mutations and develop new technologies using CRISPR to accelerate the discovery of new drugs, with a focus on immunology, oncology, and neuroscience. The LGR will receive up to $67 million in funding over the five-year collaboration period, including facilities for 24 full-time university employees funded by GSK, plus up to 14 full-time GSK employees, the company said. GSK’s artificial intelligence and machine learning group will also aid in building any necessary bioinformatics pipelines. The laboratory will be based near the University of California, San Francisco’s Mission Bay campus.

The LGR aims to automate existing CRISPR approaches so that this work can be done at scale. Ultimately, the lab’s goal is to deepen researchers’ understanding of genetics and discover new drug targets. They’re also aiming to create next-generation technologies for the pharmaceutical industry, GSK added.

The LGR will also serve as a resource for investigators at both UCSF and the University of California, Berkeley who can access and use its technology to answer their own research questions and to develop new tools.

The LGR was developed by Berkeley professor and CRISPR expert Jennifer Doudna, UCSF Professor Jonathan Weissman, and GSK CSO and President of R&D Hal Barron.

“Over the last seven years, CRISPR has transformed academic research, but until the LGR, we haven’t had a focused effort to catalyze the kind of research we know will lead to new innovation using this CRISPR tool,” Doudna said in a statement. “LGR is about building that space where creative science is partnered with the development of robust technology that will help develop tomorrow’s drugs. I think we’re going to be able to do science that none of us can even imagine today.”

The collaboration will be governed by a Joint Steering Committee with equitable UC and GSK representation, with additional joint sub-committees covering patents, scientific, and project management, GSK noted. Doudna and Weissman will sit on the committee along with GSK’s new head of functional genomics, Chris Miller.

“One of our key goals is to advance the field overall and make these tools as broadly available as possible,” Weissman added in the statement. “The LGR screening center will enable labs at UCSF and Berkeley, and having access to it will give our scientists opportunities to advance their research in ways that would be very hard for them to do in their own labs.”

ADDITIONAL ARTICLES in GenomeWeb

Jennifer Doudna, GlaxoSmithKline Establish $67M Genomics, CRISPR Research Lab Christie Rizk et al., GenomeWeb, 2019
UC Berkeley, UCSF Use $10M Gift to Launch CRISPR Initiative, Center GenomeWeb, 2014

Big Pharma’s Academic Courtship Continues With Pfizer-UCSF, Glaxo-IDI Research Pacts GenomeWeb, 2008
CSHL Genome Engineering Meeting Shows Maturing CRISPR Technologies GenomeWeb, 2016

SOURCE

Real Time Coverage @BIOConvention #BIO2019: Falling in Love with Science: Championing Science for Everyone, Everywhere

Posted in Conference Coverage with Social Media, Foundations for supporting Science and Education, Open Access Journals, Philanthropy to Academic Institution, Scientific & Biotech Conferences: Press Coverage, Scientific Publishing, Scientist: Career considerations, Women in Life Sciences, tagged #science2_0, science policy, science reporting, Scientific Publishing, women in computing, women in science, Young scientists on June 4, 2019| Leave a Comment »

Falling in Love with Science: Championing Science for Everyone, Everywhere June 4 2019

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Science and technology bring tremendous value to society in years of life and quality of life, yet the public often perceives science as difficult, irrelevant or even threatening. Moreover, the inspirational and moving stories of scientists and innovators working around the world are often hidden or misrepresented in popular culture. Whose responsibility is it to communicate science and engage the public in supporting the scientific enterprise? Can everyone be a Champion of Science and what are the solutions to enlist and engage more champions of science across generations and geographies? How do we work together to enhance transparency, accessibility and relevance of science for everyone, everywhere? Can science become more inclusive and engage hearts and not only minds?

Join this exciting session as Johnson & Johnson announces the winners of the Champions of Science – BioGENEius Storytelling Challenge, and brings together other key stakeholders in a discussion about the importance of engaging the public to fall in love in science all over again.

Sponsored by: Johnson & Johnson Innovation

Speakers

SEEMA KUMARVice President, Innovation, Global Health and Policy Communication atJohnson & Johnson Innovation

Nsikan AkpanDigital Science Producer, PBS News Hour atPBS Newshour

Arthur HorwichSterling Professor of Genetics and Professor of Pediatrics; Investigator HHMI atYale University

Siddhartha MukherjeeAssociate Professor, Medicine atColumbia University

Dr. Maria Luisa PinedaCEO & Co-Founder atEnvisagenics, Inc.

Emily WangSoftware Engineer, Facebook at2014 BioGENEius Challenge Winner

Seema: We need to solve the problem of the lack of trust in scientists. Some of JNJ winners of their acheivement program went on to become Nobel Laureates. Arthur Horwich and Hans Ullrich won the Jannsen Award for discovering compounds that could refold proteins, including protein chaperones. Many diseases occur because of protein misfolding like neuro-degenerative diseases.

Seema: Great science going on in Africa. JNJ wanted to showcase the great science in Africa. they awarded four individuals with storytelling award (Emily).

Dr. Horwich: got interested in science early on. Worked on N terminal mitochondrial signal peptides. also then got interested in how proteins fold and unfold and refold since the 1950s. He had changed the thinking of how proteins are processed within cells and over many years he had worked on this.

Emily Wang: Parents and schoolteachers prodded her curiosity in biology. The impact of day to day work of scientists is arduous but the little things can lead to advances that may help people. If passionate and have a great mentor then can get a foot in the door. Worked at Stanford in the lab.

Dr. Mukherjee: He likes to cure diseases, physican first, scientist second, writer third but he doesn’t separate this. In older times scientists wrote to think and true today. How we visualize the word, or use our hands, is similar. He takes the word translational research very seriously. Can you say in one sentence how this will help patients in three years?

There are multitude ways of love for science.

Dr. Pinela: loved asking big question and loved storytelling but asking bigger questions. Moved from Columbia and moved to US; loved the freedom and government funding situation at that time. Need the training and mentorship so mentors are a very big aspect in innovation as it led her to entrepreneurship. We need to use technology to disrupt and innovate.

Nsikin: A lot of mentors nurture curiosity. People like to see them in that story of curiosity. That is how is bases the PBS science videos: did a study on engagement and people wants a morality, and a science identity (an inner nerd in all of us i.e. spark the interest). The feedback if they focus on this has been positive.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles